US20130295022A1 - Moisturizing Foam Containing Lanolin - Google Patents
Moisturizing Foam Containing Lanolin Download PDFInfo
- Publication number
- US20130295022A1 US20130295022A1 US13/911,470 US201313911470A US2013295022A1 US 20130295022 A1 US20130295022 A1 US 20130295022A1 US 201313911470 A US201313911470 A US 201313911470A US 2013295022 A1 US2013295022 A1 US 2013295022A1
- Authority
- US
- United States
- Prior art keywords
- agent
- lanolin
- vitamin
- acid
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- Foams and, in particular, foam emulsions are complex dispersion systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam.
- U.S. Pat. No. 5,679,324 pertains to an aerosol foamable fragrance composition, translucent in its pre-dispensed state, which forms a fast-breaking foam.
- the composition contains a surfactant selected from the group consisting of ethoxylated lanolin oil derivatives, propoxylated lanolin oil derivatives, and mixtures thereof, a propellant, a fragrance, a thickener, and a cosmetic vehicle (preferably water).
- Emollients may be included, however, being translucent, the composition cannot comprise significant oil concentrations (which would make it opaque). Apparently the foam breaks spontaneously upon discharging from an aerosol container (with no need of any rubbing or sheer force application), thus making it impractical for certain applications such as intravaginal applications.
- the present invention provides a highly tolerable, hydrating lanolin containing foamable composition product for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (the “target site”).
- the foamable composition includes lanolin, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- the hydrating lanolin foam composition absorbs and stores water from the environment to thereby hydrate ⁇ the target site.
- the foamable composition further contains at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, wherein the at least one organic carrier is present in an amount selected from the group consisting of about 2% to about 5%, about 5% to about 10%, about 10% to about 20%, and about 20% to about 50%.
- at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, wherein the at least one organic carrier is present in an amount selected from the group consisting of about 2% to about 5%, about 5% to about 10%, about 10% to about 20%, and about 20% to about 50%.
- lanolin is selected from the group consisting of lanolin, wool fat, lanolin wax and hydrophobic derivatives thereof.
- a method of treating, alleviating or preventing a disorders of the skin, a body cavity or mucosal surface, wherein the disorder involves insufficient hydration as one of its etiological factors includes administering topically to a subject having the disorder, a foamed composition including lanolin, about 0.1% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of a polymeric additive selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, and water.
- the composition further includes at least one additional therapeutic agent.
- the organic carrier includes at least one therapeutically active oil.
- FIG. 1 is a plot of hydration value vs. time for two foamed lanolin compositions, illustrating the skin hydrating effect of two lanolin—containing foams.
- FIG. 2 is a bar graph illustrating the difference in skin hydration between two lanolin—containing foams and “no treatment”.
- the present invention provides a highly tolerable, hydrating lanolin-containing foamable composition product.
- the foamable lanolin containing composition for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum includes:
- a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- the foamable composition forms an expanded foam suitable for topical administration.
- Lanolin also termed “wool fat” and “wool fat alcohols” is a hydrophobic greasy, substance extracted from wool, produced from the oil glands of sheep.
- Lanolin wax is a high melting wax fraction separated from lanolin, and white lanolin is obtained by further purifications to obtain desired lanolin fractions or derivatives.
- Natural lanolin is produced, among other methods, by extraction from the wool by kneading with water, with which it readily forms an emulsion. On heating, it separates as a distinct layer at the surface of the liquid. Purification is effected by repeated treatment with water in a centrifugal machine, or by some other suitable process.
- the constituents of lanolin include cholesterol and isocholesterol, together with various esters of cholesterol and/or isocholesterol with one or more fatty acids, including, but not limited to lanoceric acid, lanopalmitic acid, carnaubic acid, myristic acid, oleic acid, cerotic acid and palmitic acid.
- lanolin is a synthetic lanolin or a synthetic lanolin derivative.
- a synthetic lanolin or a synthetic lanolin derivative is a hydrophobic derivative of lanolin, which is the result of a chemical or biochemical modification of natural lanolin.
- Synthetic lanolin or a synthetic lanolin derivative may consist of cholesterol or isocholesterol covalently linked with an organic moiety.
- synthetic lanolin derivatives include organic alcohols derived from the hydrolysis of lanolin, esters of lanolin with an aliphatic acid (e.g., acetylated lanolin), lanolin acid (a mixture of organic acids obtained from the hydrolysis of lanolin), esters of lanolin acid with aliphatic alcohols (e.g., isopropyl lanolate and cetyl lanolate).
- an aliphatic acid e.g., acetylated lanolin
- lanolin acid a mixture of organic acids obtained from the hydrolysis of lanolin
- esters of lanolin acid with aliphatic alcohols e.g., isopropyl lanolate and cetyl lanolate.
- lanolin may be determined by detection of cholesterol, a compound making up lanolin. To test, one gram of a fat is dissolved in 3 or 4 mL of acetic anhydride and 0.3 mL of sulfuric acid, resulting in a pink coloration, further changing to green and blue.
- the composition further contains at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%, or about 10% to about 20%, or about 20% to about 50% by weight.
- at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%, or about 10% to about 20%, or about 20% to about 50% by weight.
- hydrophobic organic carrier refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature.
- the identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic carrier in the foamable compositions described herein.
- the hydrophobic organic carrier is an oil, such as mineral oil.
- Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. It is typically liquid; its viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C.
- the term hydrophobic organic carrier does not include thick or semi-solid materials, such as white petrolatum, also termed “Vaseline”, which, in certain compositions is disadvantageous due to its waxy nature and semi-solid texture.
- hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources.
- Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils.
- the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
- Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids.
- said unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids.
- examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
- GLA gamma-linoleic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
- oils that possess therapeutically beneficial properties are termed “therapeutically active oil”.
- hydrophobic solvents Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oil, which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect, which is conceivably synergistic to the beneficial effect of the NSAID in the composition.
- Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
- Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties.
- Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These are chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
- the hydrophobic carrier includes at least 2% by weight silicone oil or at least 5% by weight.
- the solvent may be a mixture of two or more of the above hydrophobic solvents in any proportion.
- a further class of solvents includes “emollients” that have a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces.
- Emollients are not necessarily hydrophobic.
- suitable emollients include hexyleneglycol, propylene glycol, isostearic acid derivatives, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glyco
- the hydrophobic organic carrier includes a mixture of a hydrophobic solvent and an emollient.
- the foamable composition is a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
- a “polar solvent” is an organic solvent, typically soluble in both water and oil.
- polar solvents include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as
- the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
- PEG200 MW (molecular weight) about 190-210 kD
- PEG300 MW about 285-315 kD
- PEG400 MW about 380-420 kD
- PEG600 MW about 570-630 kD
- higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
- the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols.
- Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect.
- the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- the polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ.
- Exemplary polymeric agents are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
- the composition of the present invention includes at least one gelling agent.
- a gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site.
- Many gelling agents are known in the art to possess mucoadhesive properties.
- the gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent.
- Exemplary gelling agents that can be used in accordance with one or more embodiments of the present invention include, for example, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g.
- hydroxyethyl cellulose methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose
- guar gum hydroxypropyl guar gum
- soluble starch cationic celluloses, cationic guars, and the like
- synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
- Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981. Carbopol® 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
- the composition of the present invention includes at least one polymeric agent, which is a water-soluble cellulose ether.
- the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose and carboxymethylhydroxyethylcellulose. More preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose (Methocel).
- the composition includes a combination of a water-soluble cellulose ether; and a naturally-occurring polymeric materials, selected from the group including xanthan gum, guar gum, carrageenan gum, locust bean gum and tragacanth gum.
- the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
- Mucoadhesion/bioadhesion is defined as the attachment of synthetic or biological macromolecules to a biological tissue.
- Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia.
- Compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties.
- the bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface.
- the mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures.
- acidic synthetic polymers preferably having at least one acidic group per four repeating or monomeric subunit moie
- An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl- ⁇ -cyclodextrin.
- Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight.
- a suitable bioadhesive macromolecule is the family of acrylic acid polymers and copolymers, (e.g., Carbopol®). These polymers contain the general structure —[CH 2 —CH(COOH)—] n . Hyaluronic acid and other biologically-derived polymers may be used.
- Exemplary bioadhesive or mucoadhesive macromolecules have a molecular weight of at least 50 kDa, or at least 300 kDa, or at least 1,000 kDa.
- Favored polymeric ionizable macromolecules have not less than 2 mole percent acidic groups (e.g., COOH, SO3H) or basic groups (NH2, NRH, NR2), relative to the number of monomeric units.
- the acidic or basic groups can constitute at least 5 mole percent, or at least 10 mole percent, or at least 25, at least 50 more percent, or even up to 100 mole percent relative to the number of monomeric units of the macromolecule.
- mucoadhesive agent includes inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- the foam composition may contain a film forming component.
- the film forming component may include at least one water-insoluble alkyl cellulose or hydroxyalkyl cellulose.
- Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination.
- a plasticizer or a cross linking agent may be used to modify the polymer's characteristics.
- esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
- the composition of the present invention includes a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface.
- phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca 2+ ).
- phase change polymers include poly(N-isopropylamide), Poloxamer 407® and Smart-Gel® (Poloxamer PAA)
- the polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
- surfactants include any agent linking oil and water in the composition, in the form of emulsion.
- a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil.
- the HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
- Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
- the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
- the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic solvents.
- HLB hydrophilic lipophilic balance
- the composition contains a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
- the composition when a water in oil emulsion is desirable, contains one or more surface active agents, having an HLB value between about 2 and about 9.
- the surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants.
- Such surfactants are well known to those skilled in the therapeutic and cosmetic formulation art.
- Nonlimiting examples of possible surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myrj 49, Myrj 52 and Myrj 59; poly(oxyethylene)alkylyl ethers, such as poly(oxyethylene)cetyl ether, poly(oxyethylene)palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium la
- the surface-active agent includes at least one non-ionic surfactant.
- Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. We have surprisingly found that non-ionic surfactants alone provide foams of excellent quality, i.e. a score of “E” according to the grading scale discussed herein below.
- the surface active agent includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
- a combination of a non-ionic surfactant and an ionic surfactant is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1.
- the resultant foam has a low specific gravity, e.g., less than 0.1 g/ml.
- the stability of the composition is especially pronounced when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed.
- the ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4.
- the resultant HLB of such a blend of at least two emulsifiers is between about 9 and about 14.
- a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is between about 9 and about 14.
- the surface-active agent includes mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides.
- sucrose esters include those having high monoester content, which have higher HLB values.
- the total surface active agent is in the range of about 0.1 to about 5% of the foamable composition, and is typically less than about 2% or less than about 1%.
- a therapeutically effective foam adjuvant is included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam.
- the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof).
- fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50).
- Fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents.
- the amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains.
- Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
- the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
- fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
- fatty acids having 16 or more carbons in their carbon chain such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic
- the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond.
- a further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid.
- the carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
- fatty alcohols and fatty acids used in context of the composition of the present invention is related to their therapeutic properties per se.
- Long chain saturated and mono unsaturated fatty alcohols e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, for example, U.S. Pat. No. 4,874,794).
- Longer chain fatty alcohols e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc.
- tetracosanol hexacosanol
- heptacosanol heptacosanol
- octacosanol triacontanol, etc.
- Long chain fatty acids have also been reported to possess anti-infective characteristics.
- a combined and enhanced therapeutic effect is attained by including both a nonsteroidal immunomodulating agent and a therapeutically effective foam adjuvant in the same composition, thus providing a simultaneous anti-inflammatory and antiinfective effect from both components.
- the composition concurrently comprises a nonsteroidal immunomodulating agent, a therapeutically effective foam adjuvant and a therapeutically active oil, as detailed above.
- the foamable carrier, containing the foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
- the foam adjuvant according to preferred embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4%-2.5% (w/w) of the carrier mass.
- the therapeutic foam of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency.
- formulation excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
- Aerosol propellants are used to generate and administer the foamable composition as a foam.
- the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier.
- the propellant makes up about 3% to about 25 wt % of the foamable carrier.
- suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
- disorders of the skin, body cavity or mucosal surface involve a combination of dry and scaly skin, which can be treated with lanolin as the hydrating component of the composition and additional therapeutic modalities that address other etiological factors of the disorder.
- lanolin a steroid, a retinoid or an alpha or beta hydroxy acid.
- atopic dermatitis involves skin dryness and inflammation, which may be treated with lanolin and a steroid or an immunomodulating agent.
- the composition of the present invention is a carrier of a cosmetically or pharmaceutically active agents.
- exemplary, non binding and cosmetically or pharmaceutically active agents include, but are not limited to an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a hapten
- a pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- the foam composition of the present invention creates a stable emulsion having an acceptable shelf-life of at least one year, or at least two years at ambient temperature.
- a feature of a product for cosmetic or medical use is long term stability.
- Propellants which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- compositions containing semi-solid hydrophobic solvents e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and poor flowability and are inappropriate candidates for a foamable composition.
- Foam quality can be graded as follows:
- Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
- Grade F very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
- Grade P no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
- Grade VP dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administratable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- the breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- foams Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.1 g/mL or less than 0.05 g/mL.
- the composition are useful in treating an animal or a human patient having any one of a variety of dermatological disorders that include dry and/or scaly skin as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
- Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash;
- Bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma;
- Fungal Infections including dermatophyte infections, yeast Infections; parasitic Infections including scabies, pediculosis, creeping eruption;
- hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia greata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst;
- Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris;
- Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid;
- Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcoma;
- Bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease;
- Pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation;
- Inflammatory reactions including drug eruptions, toxic epidermal necrolysis; erythema multiforme, erythema nodosum, granuloma annulare.
- compositions are also useful in the therapy of non-dermatological disorders by providing transdermal delivery of an active nonsteroidal immunomodulating agent that is effective against non-dermatological disorders.
- composition is topically applied to a body cavity or mucosal surface (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum) to treat conditions such as chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis,
- the improvement rendered by LAN1 was in the range of 16.7%-22.4%, and for LAN2, there was a 24.9%-19.6% improvement.
- the skin moisture was improved by 20%-28%.
- 12% ammonium lactate is a prescription drug with known side effects
- the lanolin foam compositions can be generally considered as safe and can be used daily without safety concerns.
Abstract
Description
- This application is a continuation-in-part application of co-pending International Patent Application No. IB03/005527 designating the United States and filed on Oct. 24, 2003, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/492,546, filed on Nov. 29, 2002, both entitled “Cosmetic and Pharmaceutical Foam,” and which also claims the benefit of priority under 35 USC§119(a) to Israeli Patent Appl. No. 152486, filed Oct. 25, 2002, all of which are hereby incorporated in their entirety by reference.
- This application is a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/911,367, filed on Aug. 4, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/492,385, filed on Aug. 4, 2003, both entitled “Foam Carrier Containing Amphiphilic Copolymer Gelling Agent” and both hereby incorporated in their entirety by reference.
- Foams and, in particular, foam emulsions are complex dispersion systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam.
- There have been a few attempts to create foams containing lanolin.
- U.S. Pat. No. 5,679,324 pertains to an aerosol foamable fragrance composition, translucent in its pre-dispensed state, which forms a fast-breaking foam. The composition contains a surfactant selected from the group consisting of ethoxylated lanolin oil derivatives, propoxylated lanolin oil derivatives, and mixtures thereof, a propellant, a fragrance, a thickener, and a cosmetic vehicle (preferably water). Emollients may be included, however, being translucent, the composition cannot comprise significant oil concentrations (which would make it opaque). Apparently the foam breaks spontaneously upon discharging from an aerosol container (with no need of any rubbing or sheer force application), thus making it impractical for certain applications such as intravaginal applications.
- The present invention provides a highly tolerable, hydrating lanolin containing foamable composition product for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (the “target site”). The foamable composition includes lanolin, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The hydrating lanolin foam composition absorbs and stores water from the environment to thereby hydrate\ the target site.
- According to further embodiments of the present invention, the foamable composition further contains at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, wherein the at least one organic carrier is present in an amount selected from the group consisting of about 2% to about 5%, about 5% to about 10%, about 10% to about 20%, and about 20% to about 50%.
- According to further embodiments of the present invention, lanolin is selected from the group consisting of lanolin, wool fat, lanolin wax and hydrophobic derivatives thereof.
- According to further embodiments of the present invention, there is provided a method of treating, alleviating or preventing a disorders of the skin, a body cavity or mucosal surface, wherein the disorder involves insufficient hydration as one of its etiological factors. The method includes administering topically to a subject having the disorder, a foamed composition including lanolin, about 0.1% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of a polymeric additive selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, and water.
- According to still further embodiments of method according to the present invention, the composition further includes at least one additional therapeutic agent.
- According to yet further embodiments of method according to the present invention, the organic carrier includes at least one therapeutically active oil.
- The invention is described with reference to the figures, which are presented for the purpose of illustration and are not intended to be limiting of the invention.
-
FIG. 1 is a plot of hydration value vs. time for two foamed lanolin compositions, illustrating the skin hydrating effect of two lanolin—containing foams. -
FIG. 2 is a bar graph illustrating the difference in skin hydration between two lanolin—containing foams and “no treatment”. - The present invention provides a highly tolerable, hydrating lanolin-containing foamable composition product.
- All % values are provided on a weight (w/w) basis.
- According to one or more embodiments of the present invention, the foamable lanolin containing composition for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein “target site”) includes:
- (1) lanolin;
- (2) about 0.1% to about 5% by weight of a surface-active agent;
- (3) about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and
- (4) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
- Water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms an expanded foam suitable for topical administration.
- Lanolin, also termed “wool fat” and “wool fat alcohols” is a hydrophobic greasy, substance extracted from wool, produced from the oil glands of sheep. Lanolin wax is a high melting wax fraction separated from lanolin, and white lanolin is obtained by further purifications to obtain desired lanolin fractions or derivatives.
- Natural lanolin is produced, among other methods, by extraction from the wool by kneading with water, with which it readily forms an emulsion. On heating, it separates as a distinct layer at the surface of the liquid. Purification is effected by repeated treatment with water in a centrifugal machine, or by some other suitable process.
- The constituents of lanolin include cholesterol and isocholesterol, together with various esters of cholesterol and/or isocholesterol with one or more fatty acids, including, but not limited to lanoceric acid, lanopalmitic acid, carnaubic acid, myristic acid, oleic acid, cerotic acid and palmitic acid.
- In one or more embodiments of the present invention, lanolin is a synthetic lanolin or a synthetic lanolin derivative. In the context of the present invention, a synthetic lanolin or a synthetic lanolin derivative is a hydrophobic derivative of lanolin, which is the result of a chemical or biochemical modification of natural lanolin. Synthetic lanolin or a synthetic lanolin derivative may consist of cholesterol or isocholesterol covalently linked with an organic moiety. By way of non-limiting examples, synthetic lanolin derivatives include organic alcohols derived from the hydrolysis of lanolin, esters of lanolin with an aliphatic acid (e.g., acetylated lanolin), lanolin acid (a mixture of organic acids obtained from the hydrolysis of lanolin), esters of lanolin acid with aliphatic alcohols (e.g., isopropyl lanolate and cetyl lanolate).
- The presence of lanolin may be determined by detection of cholesterol, a compound making up lanolin. To test, one gram of a fat is dissolved in 3 or 4 mL of acetic anhydride and 0.3 mL of sulfuric acid, resulting in a pink coloration, further changing to green and blue.
- Optionally, the composition further contains at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%, or about 10% to about 20%, or about 20% to about 50% by weight.
- A “hydrophobic organic carrier” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature. The identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic carrier in the foamable compositions described herein.
- In one or more embodiments, the hydrophobic organic carrier is an oil, such as mineral oil. Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. It is typically liquid; its viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C. In one or more embodiments, the term hydrophobic organic carrier does not include thick or semi-solid materials, such as white petrolatum, also termed “Vaseline”, which, in certain compositions is disadvantageous due to its waxy nature and semi-solid texture.
- According to one or more embodiments, hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources. Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils. By way of example, the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
- Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids. In one or more embodiments, said unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Such unsaturated fatty acids are known for their skin-conditioning effect, which contribute to the therapeutic benefit of the present foamable composition. Thus, the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof. In the context of the present invention, oils that possess therapeutically beneficial properties are termed “therapeutically active oil”.
- Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oil, which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect, which is conceivably synergistic to the beneficial effect of the NSAID in the composition.
- Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
- Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These are chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
- In one or more embodiments, the hydrophobic carrier includes at least 2% by weight silicone oil or at least 5% by weight.
- The solvent may be a mixture of two or more of the above hydrophobic solvents in any proportion.
- A further class of solvents includes “emollients” that have a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces. Emollients are not necessarily hydrophobic. Examples of suitable emollients include hexyleneglycol, propylene glycol, isostearic acid derivatives, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, sucrose esters of fatty acids, octyl hydroxystearate and mixtures thereof.
- According to one or more embodiments of the present invention, the hydrophobic organic carrier includes a mixture of a hydrophobic solvent and an emollient. According to one or more embodiments, the foamable composition is a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
- A “polar solvent” is an organic solvent, typically soluble in both water and oil. Examples of polar solvents include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1-menthol, dioxolane, ethylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid; lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof.
- According to one or more embodiments, the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
- According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1%.
- The polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ. Exemplary polymeric agents, are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
- In one or more embodiments, the composition of the present invention includes at least one gelling agent. A gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site. Many gelling agents are known in the art to possess mucoadhesive properties.
- The gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent. Exemplary gelling agents that can be used in accordance with one or more embodiments of the present invention include, for example, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose), guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars, and the like, and synthetic polymeric materials, such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
- Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981. Carbopol® 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
- In one or more embodiment, the composition of the present invention includes at least one polymeric agent, which is a water-soluble cellulose ether. Preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose and carboxymethylhydroxyethylcellulose. More preferably, the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose (Methocel). In one or more embodiments, the composition includes a combination of a water-soluble cellulose ether; and a naturally-occurring polymeric materials, selected from the group including xanthan gum, guar gum, carrageenan gum, locust bean gum and tragacanth gum.
- Yet, in other embodiments, the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
- Mucoadhesion/bioadhesion is defined as the attachment of synthetic or biological macromolecules to a biological tissue. Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia. Compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties. The bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface. The mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures. An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl-β-cyclodextrin. Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight.
- A suitable bioadhesive macromolecule is the family of acrylic acid polymers and copolymers, (e.g., Carbopol®). These polymers contain the general structure —[CH2—CH(COOH)—]n. Hyaluronic acid and other biologically-derived polymers may be used.
- Exemplary bioadhesive or mucoadhesive macromolecules have a molecular weight of at least 50 kDa, or at least 300 kDa, or at least 1,000 kDa. Favored polymeric ionizable macromolecules have not less than 2 mole percent acidic groups (e.g., COOH, SO3H) or basic groups (NH2, NRH, NR2), relative to the number of monomeric units. The acidic or basic groups can constitute at least 5 mole percent, or at least 10 mole percent, or at least 25, at least 50 more percent, or even up to 100 mole percent relative to the number of monomeric units of the macromolecule.
- Yet, another group of mucoadhesive agent includes inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSIL 200 (DEGUSSA).
- Many mucoadhesive agents are known in the art to also possess gelling properties.
- The foam composition may contain a film forming component. The film forming component may include at least one water-insoluble alkyl cellulose or hydroxyalkyl cellulose. Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination. In addition, a plasticizer or a cross linking agent may be used to modify the polymer's characteristics. For example, esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
- In one or more embodiments, the composition of the present invention includes a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface. Such phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca2+).
- Non-limiting examples of phase change polymers include poly(N-isopropylamide), Poloxamer 407® and Smart-Gel® (Poloxamer PAA)
- The polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
- Surface-active agents (also termed “surfactants”) include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
- According to one or more embodiments of the present invention, the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic solvents. Thus, in one or more embodiments, the composition contains a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14. Yet, in other embodiments, when a water in oil emulsion is desirable, the composition contains one or more surface active agents, having an HLB value between about 2 and about 9.
- The surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the therapeutic and cosmetic formulation art. Nonlimiting examples of possible surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as
Myrj 45, Myrj 49, Myrj 52 and Myrj 59; poly(oxyethylene)alkylyl ethers, such as poly(oxyethylene)cetyl ether, poly(oxyethylene)palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines. - In one or more embodiments of the present invention, the surface-active agent includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. We have surprisingly found that non-ionic surfactants alone provide foams of excellent quality, i.e. a score of “E” according to the grading scale discussed herein below.
- In one or more embodiments, the surface active agent includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
- In one or more embodiments of the present invention, a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1. The resultant foam has a low specific gravity, e.g., less than 0.1 g/ml.
- It has been surprisingly discovered that the stability of the composition is especially pronounced when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed. The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1:8 and 8:1, or at a ratio of 4:1 to 1:4. The resultant HLB of such a blend of at least two emulsifiers is between about 9 and about 14.
- Thus, in an exemplary embodiment, a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1:8 and 8:1, or at a ratio of 4:1 to 1:4, wherein the HLB of the combination of emulsifiers is between about 9 and about 14.
- In one or more embodiments of the present invention, the surface-active agent includes mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides. Suitable sucrose esters include those having high monoester content, which have higher HLB values.
- The total surface active agent is in the range of about 0.1 to about 5% of the foamable composition, and is typically less than about 2% or less than about 1%.
- Preferably, a therapeutically effective foam adjuvant is included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam. In one or more embodiments of the present invention, the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). Fatty alcohols, derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents. The amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains. Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
- In one or more embodiments of the present invention, the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof. As for fatty alcohols, the amount of fatty acids required to support the foam system is inversely related to the length of its carbon chain.
- Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond. A further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid. The carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
- An important property of the fatty alcohols and fatty acids used in context of the composition of the present invention is related to their therapeutic properties per se. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, for example, U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc., are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics.
- Thus, in preferred embodiments of the present invention, a combined and enhanced therapeutic effect is attained by including both a nonsteroidal immunomodulating agent and a therapeutically effective foam adjuvant in the same composition, thus providing a simultaneous anti-inflammatory and antiinfective effect from both components. Furthermore, in a further preferred embodiment, the composition concurrently comprises a nonsteroidal immunomodulating agent, a therapeutically effective foam adjuvant and a therapeutically active oil, as detailed above. Such combination provides an even more enhanced therapeutic benefit. Thus, the foamable carrier, containing the foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
- The foam adjuvant according to preferred embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4%-2.5% (w/w) of the carrier mass.
- The therapeutic foam of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency. Such excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
- Aerosol propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier. The propellant makes up about 3% to about 25 wt % of the foamable carrier. Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
- Several disorders of the skin, body cavity or mucosal surface (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum), involve a combination of dry and scaly skin, which can be treated with lanolin as the hydrating component of the composition and additional therapeutic modalities that address other etiological factors of the disorder. For example, psoriasis involves dry and scaly skin, as well as inflammation, excessive cell proliferation and inadequate cell differentiation, which can be alleviated by treatment with lanolin and an additional active agent, such as a steroid, a retinoid or an alpha or beta hydroxy acid. Likewise, atopic dermatitis involves skin dryness and inflammation, which may be treated with lanolin and a steroid or an immunomodulating agent.
- Thus, in one or more embodiments, the composition of the present invention is a carrier of a cosmetically or pharmaceutically active agents. Exemplary, non binding and cosmetically or pharmaceutically active agents include, but are not limited to an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an steroidal antiinflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide), silicone oxide, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.
- A pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
- The foam composition of the present invention creates a stable emulsion having an acceptable shelf-life of at least one year, or at least two years at ambient temperature. A feature of a product for cosmetic or medical use is long term stability. Propellants, which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
- The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam. Compositions containing semi-solid hydrophobic solvents, e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and poor flowability and are inappropriate candidates for a foamable composition.
- Foam quality can be graded as follows:
- Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
- Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
- Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
- Grade F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
- Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
- Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
- Topically administratable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
- As further aspect of the foam is breakability. The breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
- Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.1 g/mL or less than 0.05 g/mL.
- By including lanolin and optional active agents in the compositions of the present invention, the composition are useful in treating an animal or a human patient having any one of a variety of dermatological disorders that include dry and/or scaly skin as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
- Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash;
- Bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma;
- Fungal Infections including dermatophyte infections, yeast Infections; parasitic Infections including scabies, pediculosis, creeping eruption;
- Viral Infections;
- Disorders of hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia greata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst;
- Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris;
- Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid;
- Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcoma;
- Reactions to sunlight including sunburn, chronic effects of sunlight, photosensitivity;
- Bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease;
- Pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation;
- Disorders of comification including ichthyosis, keratosis pilaris, calluses and corns, actinic keratosis;
- Pressure sores;
- Disorders of sweating; and
- Inflammatory reactions including drug eruptions, toxic epidermal necrolysis; erythema multiforme, erythema nodosum, granuloma annulare.
- According to one or more embodiments of the present invention, the compositions are also useful in the therapy of non-dermatological disorders by providing transdermal delivery of an active nonsteroidal immunomodulating agent that is effective against non-dermatological disorders.
- The same advantage is expected when the composition is topically applied to a body cavity or mucosal surface (e.g., the mucosa of the nose, mouth, eye, ear, vagina or rectum) to treat conditions such as chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, cnal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
- The following examples exemplify the therapeutic kits and pharmacological compositions and methods described herein. The examples are for the purposes of illustration only and are not intended to be limiting of the invention.
-
-
Composition No: LAN1 LAN2 LAN3 LAN4 Ingredient % Lanolin 5.00 15.00 30.00 40.00 Mineral oil light 20.00 — — — MCT oil — 10.00 — — Glyceryl monostearate 0.45 0.45 0.45 1.00 Stearyl alcohol 0.95 — — — Xanthan gum 0.28 — — — Methocel K100M 0.28 — — — Polysorbate 80 0.95 0.95 0.95 0.95 PEG-40 Stearate 2.80 2.80 2.80 2.80 Preservative 0.25 0.25 0.25 0.25 Propellant 8.00 8.00 8.00 8.00 Water To 100 To 100 To 100 To 100 Composition Properties Emulsion color White White White White Foam Density 0.06 0.06 0.08 0.08 -
-
Composition No: LAN5 LAN6 LAN7 LAN8 Ingredient % Lanolin 5.00 5.00 5.00 5.00 Mineral oil 20.00 20.00 20.00 — IPP 10.00 — — — IPM — 10.00 10.00 — Beeswax 2.00 2.00 2.00 2.00 Glyceryl oleate 0.80 0.80 0.80 0.80 Glyceryl monostearate SE 0.80 0.80 0.80 0.80 Arlacel P135 0.40 0.40 0.40 0.40 Ceteth-2 (Lipocol C2) 6.00 5.00 5.00 5.00 Arlatone 2121 0.50 0.50 0.50 0.50 Sucrose ester SP30 0.80 0.80 0.80 0.80 Sucrose ester SP10 0.80 0.80 0.80 0.80 Aloe vera extract 0.10 0.10 0.10 0.10 Xanthan gum 0.40 0.40 0.40 0.40 Magnesium sulfate — 0.20 0.20 0.20 D-Pantenol 4.00 4.00 4.00 4.00 Disodium EDTA 0.20 0.40 0.40 0.40 Alpha Bisabolol — 0.20 0.20 0.20 Benzalkonium chloride (50% sol) 0.20 0.20 0.20 0.20 Zinc oxide 10.00 10.00 — — Water To 100 To 100 To 100 To 100 Composition Properties Emulsion color White White White White Foam Density 0.072 0.086 0.088 0.070 - Six subjects were treated with foam compositions LAN1 and LAN2, on their arm. Skin hydration was measured using Corneometer CM825 for 240 minutes (6 hours) at the treatment sites and at an untreated site. The skin hydration values for the two lanolin based foams vs. “no treatment” is presented in Table 1 below and is shown in
FIG. 1 . Table 2 provides the “delta” values, i.e., the difference between the hydration effect of LAN1 and LAN2, and the hydration value of the non-treated sites, which is illustrated inFIG. 2 . As demonstrated in Tables 1 and 2, LAN1 and LAN2 foams provided significant hydration for at least 6 hours. The improvement rendered by LAN1 was in the range of 16.7%-22.4%, and for LAN2, there was a 24.9%-19.6% improvement. For comparison purposes, in a parallel group, which was treated with a commercial 12% ammonium lactate lotion, the skin moisture was improved by 20%-28%. Notable, while 12% ammonium lactate is a prescription drug with known side effects, the lanolin foam compositions can be generally considered as safe and can be used daily without safety concerns. -
TABLE 1 Moisturizing Test: Two Lanolin Based Foams vs. No Treatment, using Corneometer CM825 Corneometer CM825 Values Time (min) No Treatment LAN1 LAN2 0 41 40 38 60 41 48 47 120 40 47 49 180 40 47 49 240 42 49 49 -
TABLE 2 Moisturizing Test: The Absolute (Incremental) Skin Hydrating Effect of Two Lanolin, Using Corneometer CM825 Corneometer CM825 Values Time (min) LAN1 LAN2 60 7.75 (+19.4%) 9.46 (+24.9%) 120 6.71 (+16.7%) 11.04 (+29.1%) 180 6.75 (+16.9%) 11.25 (+29.6%) 240 8.96 (+22.4%) 11.21 (+29.5%)
Claims (23)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL152486 | 2002-10-25 | ||
IL15248602A IL152486A0 (en) | 2002-10-25 | 2002-10-25 | Alcohol-free cosmetic and pharmaceutical foam carrier |
US42954602P | 2002-11-29 | 2002-11-29 | |
US49238503P | 2003-08-04 | 2003-08-04 | |
PCT/IB2003/005527 WO2004037225A2 (en) | 2002-10-25 | 2003-10-24 | Cosmetic and pharmaceutical foam |
US10/911,367 US20050069566A1 (en) | 2003-08-04 | 2004-08-04 | Foam carrier containing amphiphilic copolymeric gelling agent |
US11/099,942 US8486376B2 (en) | 2002-10-25 | 2005-04-06 | Moisturizing foam containing lanolin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/099,942 Continuation US8486376B2 (en) | 2002-10-25 | 2005-04-06 | Moisturizing foam containing lanolin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130295022A1 true US20130295022A1 (en) | 2013-11-07 |
Family
ID=34864843
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/099,942 Active 2028-04-02 US8486376B2 (en) | 2002-10-25 | 2005-04-06 | Moisturizing foam containing lanolin |
US13/911,470 Abandoned US20130295022A1 (en) | 2002-10-25 | 2013-06-06 | Moisturizing Foam Containing Lanolin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/099,942 Active 2028-04-02 US8486376B2 (en) | 2002-10-25 | 2005-04-06 | Moisturizing foam containing lanolin |
Country Status (1)
Country | Link |
---|---|
US (2) | US8486376B2 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080138296A1 (en) * | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10716740B2 (en) | 2015-03-24 | 2020-07-21 | The Procter & Gamble Company | Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8119150B2 (en) * | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
WO2007054818A2 (en) | 2005-05-09 | 2007-05-18 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
PL2526930T3 (en) * | 2005-06-01 | 2014-05-30 | Glaxosmithkline Ip Dev Ltd | Vitamin formulation |
PT2020221E (en) * | 2007-06-19 | 2012-05-30 | Neubourg Skin Care Gmbh & Co Kg | Dms (derma membrane structure) in foaming creams |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US9676696B2 (en) | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
US20120064013A1 (en) * | 2010-02-03 | 2012-03-15 | David Marcos | Foamable topical composition |
GB2479891A (en) * | 2010-04-27 | 2011-11-02 | David Chamberlain | Foaming solution to provide acoustic dampening in the ear canal |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
GB2525520B (en) | 2012-12-27 | 2019-07-10 | Kimberly Clark Co | Water soluble farnesol analogs and their use |
BR112015013756B1 (en) | 2012-12-27 | 2021-07-20 | Kimberly-Clark Worldwide, Inc. | METHOD OF ADJUSTING THE SOLUBILITY OF A BOTANICAL OIL IN WATER, BOTANICAL OIL, SCARF, AND, ABSORBING ARTICLE |
CA2904507C (en) | 2013-03-10 | 2021-05-04 | Peritech Pharma Ltd. | Topical compositions and methods of treatment of topical disorders |
FR3009956B1 (en) * | 2013-08-29 | 2018-05-11 | L'oreal | MOISTURIZING COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION; MOISTURIZING CARE PROCESS |
MX363386B (en) | 2013-10-03 | 2019-03-20 | Dow Pharmaceutical Sciences | Stabilized efinaconazole compositions. |
CA2931144C (en) | 2013-11-22 | 2020-02-04 | Dow Pharmaceutical Sciences, Inc. | Anti-infective methods, compositions, and devices |
KR102271753B1 (en) | 2014-02-14 | 2021-06-30 | 미션 파머컬 캄파니 | Spray delivery device |
US11007151B2 (en) | 2014-02-14 | 2021-05-18 | Mission Pharmacal Company | Sprayable composition containing zinc oxide and a fluoro-olefin propellant |
CN107708665B (en) | 2015-03-23 | 2022-07-22 | 贝尔生物制药有限公司 | Pharmaceutical tetracycline compositions for dermatological use |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5635469A (en) * | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
US5705472A (en) * | 1995-07-18 | 1998-01-06 | Petroferm Inc. | Neutral aqueous cleaning composition |
US5939376A (en) * | 1997-09-25 | 1999-08-17 | Colgate Palmolive Company | Liquid cleaning compositions containing an organic ester foam control agent |
US6551604B1 (en) * | 1999-06-28 | 2003-04-22 | The Procter & Gamble Company | Skin care compositions |
Family Cites Families (872)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1159250A (en) | 1914-05-01 | 1915-11-02 | Frank Moulton | Vaginal irrigator. |
US1666684A (en) | 1926-01-15 | 1928-04-17 | Carstens Mfg Co H | Vaginal douche |
US1924972A (en) | 1929-04-15 | 1933-08-29 | Carl J Beckert | Stabilized egg product |
US2085733A (en) | 1935-07-15 | 1937-07-06 | John C Bird | Shaving cream |
US2390921A (en) | 1943-03-23 | 1945-12-11 | Ethel Hudson Clark | Applicator for facial creams |
US2524590A (en) | 1946-04-22 | 1950-10-03 | Carsten F Boe | Emulsion containing a liquefied propellant gas under pressure and method of spraying same |
US2586287A (en) | 1948-12-11 | 1952-02-19 | Colagte Palmolive Peet Company | Aluminum sulfamate antiperspirant preparation |
US2617754A (en) | 1949-08-29 | 1952-11-11 | Procter & Gamble | Cosmetic cream |
DE933486C (en) | 1949-10-02 | 1955-09-29 | Ibm Deutschland | Electromechanical computing device with counter value setting device |
US3062715A (en) | 1953-11-18 | 1962-11-06 | George S Pfaus | Vaginal tablet |
US2767712A (en) | 1954-03-01 | 1956-10-23 | Neil S Waterman | Medicinal applicator |
GB808104A (en) | 1955-01-04 | 1959-01-28 | Udylite Res Corp | Electrodeposition of copper from aqueous alkaline cyanide solutions |
GB808105A (en) | 1956-06-15 | 1959-01-28 | Ici Ltd | New pharmaceutical compositions |
US3092555A (en) | 1958-04-21 | 1963-06-04 | Roy H Horn | Relatively collapsible aerosol foam compositions |
US3144386A (en) | 1958-05-09 | 1964-08-11 | Merck & Co Inc | Mastitis aerosol foam |
US2968628A (en) | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3178352A (en) * | 1959-02-27 | 1965-04-13 | Erickson Roy | Shaving method and composition therefor |
US3141821A (en) * | 1959-03-17 | 1964-07-21 | Lehn & Fink Products Corp | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
US3004894A (en) | 1959-04-07 | 1961-10-17 | Upjohn Co | Therapeutic composition comprising tetracycline and a dioxolane |
GB922930A (en) | 1959-09-21 | 1963-04-03 | Sunnen Joseph | Spermicidal composition and method of making same |
US3142420A (en) | 1959-11-09 | 1964-07-28 | Neotechnic Eng Ltd | Metering dispenser for aerosol with fluid pressure operated piston |
US3092255A (en) | 1960-02-05 | 1963-06-04 | Robert F Hohman | Sorting apparatus |
US3067784A (en) | 1960-04-14 | 1962-12-11 | Esta Medical Lab Inc | Adapter connecting aerosol container valve stem to dispenser for filling said dispenser |
NL270627A (en) | 1960-10-26 | |||
US3154075A (en) | 1960-11-02 | 1964-10-27 | Norwich Pharma Co | Vaginal applicator |
GB998490A (en) | 1961-06-03 | 1965-07-14 | Albert Fritz Albach | A foam projector |
DE1926796U (en) | 1961-10-12 | 1965-11-11 | Heidolph Elektro K G | FAN. |
US3261695A (en) | 1962-12-24 | 1966-07-19 | Gen Foods Corp | Process for preparing dehydrated foods |
US3330730A (en) | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
US3252859A (en) | 1962-10-24 | 1966-05-24 | Masti Kure Company Inc | Colloidal silica-oil composition and method of using same |
US3244589A (en) | 1962-10-26 | 1966-04-05 | Sunnen | Alkyl phenoxy polyethoxy ether spermicidal aerosol |
US3298919A (en) * | 1962-12-26 | 1967-01-17 | Dow Corning | Shaving cream containing polysiloxanes |
FR1355607A (en) | 1963-01-22 | 1964-03-20 | Improvements to cannula probes and their applications | |
US3149543A (en) | 1963-03-04 | 1964-09-22 | Ingersoll Rand Co | Non-lubricated piston |
GB1026831A (en) | 1963-05-31 | 1966-04-20 | Mediline Ag | Preparations for use in feminine hygiene |
GB1081949A (en) | 1963-08-12 | 1967-09-06 | Avon Prod Inc | Improvements in cosmetic mask |
US3333333A (en) | 1963-08-14 | 1967-08-01 | Rca Corp | Method of making magnetic material with pattern of embedded non-magnetic material |
US3236457A (en) | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3263867A (en) | 1963-12-26 | 1966-08-02 | Valve Corp Of America | Metering button-type aerosol actuator |
US3395214A (en) | 1964-01-09 | 1968-07-30 | Scholl Mfg Co Inc | Antiperspirant composition providing a readily collapsible sprayable foam |
US3278093A (en) | 1964-01-13 | 1966-10-11 | Valve Corp Of America | Metering and non-metering aerosol actuator button |
GB1052724A (en) | 1964-04-27 | |||
US3303970A (en) | 1964-07-14 | 1967-02-14 | Jerome Marrow | Device for simultaneously dispensing from plural sources |
US3395215A (en) | 1964-10-15 | 1968-07-30 | Colgate Palmolive Co | Pressurized lotion composition |
US3384541A (en) | 1964-10-28 | 1968-05-21 | William G. Clark | Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants |
US3263869A (en) | 1964-11-03 | 1966-08-02 | Calmar Inc | Liquid dispenser with overcap |
US3419658A (en) | 1965-01-25 | 1968-12-31 | Du Pont | Nonaqueous aerosol foams containing mineral oil |
US3346451A (en) | 1965-01-27 | 1967-10-10 | S E Massengill Company | Concentrated liquid lactic acid douche preparation containing aromatics |
US3301444A (en) | 1965-08-12 | 1967-01-31 | Oel Inc | Aerosol metering valve |
US3456052A (en) | 1965-09-28 | 1969-07-15 | Garrett Lab Inc | Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol |
GB1121358A (en) | 1965-10-21 | 1968-07-24 | Bristol Myers Co | Aerosol manufacture |
BE692228A (en) | 1966-01-10 | 1967-07-05 | ||
US3401849A (en) | 1966-05-24 | 1968-09-17 | Robert L. Weber | Low force metering valve |
US3886084A (en) | 1966-09-29 | 1975-05-27 | Champion Int Corp | Microencapsulation system |
US3377004A (en) | 1966-10-03 | 1968-04-09 | Gen Mills Inc | Metered dispensing container |
GB1201918A (en) | 1966-12-21 | 1970-08-12 | Bespak Industries Ltd | Improvements in or relating to valves for pressurised dispensers |
US3527559A (en) | 1967-01-05 | 1970-09-08 | Standard Pharmacal Corp | Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent |
US3366494A (en) | 1967-02-15 | 1968-01-30 | Du Pont | Pressurized aerosol food emulsions |
US3561262A (en) | 1967-10-26 | 1971-02-09 | Magnaflux Corp | Water soluble developer |
US3540448A (en) | 1968-01-17 | 1970-11-17 | Joseph Sunnen | Rechargeable applicator for dispensing substances in a foam condition |
US3563098A (en) | 1968-06-28 | 1971-02-16 | Rex Chainbelt Inc | Automatic quick release mechanism |
US3559890A (en) | 1968-09-03 | 1971-02-02 | William R Brooks | Foam dispenser |
US3667461A (en) | 1968-11-05 | 1972-06-06 | Paul A Zamarra | Disposable syringe |
CA975500A (en) | 1969-02-06 | 1975-09-30 | Joseph G. Spitzer | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process |
US3866800A (en) | 1969-02-12 | 1975-02-18 | Alberto Culver Co | Non-pressurized package containing self-heating products |
US3966090A (en) | 1969-02-17 | 1976-06-29 | Dart Industries Inc. | Package for dispensing an antiseptic composition |
US4001391A (en) | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
US3819524A (en) | 1969-06-17 | 1974-06-25 | Colgate Palmolive Co | Cosmetic composition for thermal dispensing |
US3577518A (en) | 1969-07-18 | 1971-05-04 | Nat Patent Dev Corp | Hydrophilic hairspray and hair setting preparations |
US3787566A (en) * | 1969-07-29 | 1974-01-22 | Holliston Labor Inc | Disinfecting aerosol compositions |
BE759520A (en) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | ASPIRIN COMPOSITIONS |
GB1353381A (en) | 1971-02-04 | 1974-05-15 | Wilkinson Sword Ltd | Substituted p-menthanes and compositions containing them |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
GB1351762A (en) | 1971-02-14 | 1974-05-01 | Wilkinson Sword Ltd | Tobacco and tobacco-containing manufactures |
CA958338A (en) | 1971-03-08 | 1974-11-26 | Chung T. Shin | Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation |
US3770648A (en) | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
BE788788A (en) | 1971-09-13 | 1973-03-13 | Treuhandvereinigung Ag | PRODUCT FOR PRESERVING, PROMOTING AND RESTORING HAIR AND METHOD OF MANUFACTURING THIS PRODUCT |
SE358308B (en) | 1971-11-26 | 1973-07-30 | Pharmacia Ab | |
US3997467A (en) | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
CH569128B5 (en) | 1971-12-30 | 1975-11-14 | Ciba Geigy Ag | |
JPS4892282U (en) | 1972-02-05 | 1973-11-06 | ||
US3963833A (en) | 1972-06-02 | 1976-06-15 | Colgate-Palmolive Company | Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt |
US3841525A (en) | 1972-06-14 | 1974-10-15 | N Siegel | Aerosol spray device with cam activator |
US3849580A (en) | 1972-09-05 | 1974-11-19 | American Home Prod | Aerosol dispensing system for anhydrous edible fat compositions |
US3751562A (en) | 1972-09-22 | 1973-08-07 | Princeton Biomedix | Medicated gelled oils |
US3970584A (en) | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US4439416A (en) | 1973-03-23 | 1984-03-27 | Colgate-Palmolive Company | Self-heating shaving composition |
GB1423179A (en) | 1973-05-16 | 1976-01-28 | Wilkinson Sword Ltd | Pressurised shaving foam dispensers |
YU36328B (en) | 1973-07-18 | 1983-06-30 | Elastin Werk Ag | Method of manufacturing red foils for packing sausages |
US4110426A (en) | 1973-07-24 | 1978-08-29 | Colgate-Palmolive Company | Method of treating skin and hair with a self-heated cosmetic |
US3865275A (en) | 1973-07-30 | 1975-02-11 | Raymond Lee Organization Inc | Apparatus for operating an aerosol can |
US3929985A (en) | 1974-01-18 | 1975-12-30 | Richardson Merrell Inc | Anhydrous candicidin foam compositions |
DE2501548A1 (en) | 1974-01-25 | 1975-07-31 | Procter & Gamble | ORAL TREATMENT PRODUCTS |
GB1457671A (en) | 1974-01-31 | 1976-12-08 | Wilkinson Sword Ltd | Flavour |
US3923970A (en) | 1974-03-29 | 1975-12-02 | Carter Wallace | Stable aerosol shaving foams containing mineral oil |
US3962150A (en) | 1974-04-10 | 1976-06-08 | Richardson-Merrell Inc. | Foam producing cleansing compositions |
US3966632A (en) | 1974-06-06 | 1976-06-29 | G. D. Searle & Co. | Vegetable oil emulsion |
US4145411A (en) | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
JPS5729213B2 (en) | 1974-11-12 | 1982-06-21 | ||
US3952916A (en) | 1975-01-06 | 1976-04-27 | Warner-Lambert Company | Automatic dispenser for periodically actuating an aerosol container |
US4019657A (en) | 1975-03-03 | 1977-04-26 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols |
US3970219A (en) | 1975-03-03 | 1976-07-20 | Spitzer Joseph G | Aerosol containers for foaming and delivering aerosols and process |
US4018396A (en) | 1975-05-05 | 1977-04-19 | Bechtel International Corporation | Embedded housing for ore crusher |
US3993224A (en) | 1975-09-08 | 1976-11-23 | Aerosol Investments, Ltd. | Spout for two-component resin dispenser |
DE2608226A1 (en) | 1976-02-28 | 1977-09-08 | Haarmann & Reimer Gmbh | AGENTS WITH PHYSIOLOGICAL COOLING EFFECT |
US4100426A (en) | 1976-03-10 | 1978-07-11 | Square D Company | Load controlling means |
US4102995A (en) | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
US4124149A (en) | 1976-07-19 | 1978-11-07 | Spitzer Joseph G | Aerosol container with position-sensitive shut-off valve |
CA1089368A (en) | 1976-08-02 | 1980-11-11 | Daniel C. Geary | Polyethoxylated fatty alcohol in antiperspirant sticks |
IL52045A (en) | 1976-08-25 | 1979-12-30 | Mundipharma Ag | Sprayable germicidal foam compositions |
US4310510A (en) | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
US4252787A (en) | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
IT1114950B (en) | 1977-12-30 | 1986-02-03 | Porro Marcella | COMPOSITIONS FOR ACNE TREATMENT AND THERAPY |
US4386104A (en) | 1977-04-19 | 1983-05-31 | Nazzaro Porro Marcella | Process for the treatment of acne |
GB2004746B (en) | 1977-10-03 | 1982-03-10 | Scherico Ltd | Stable hopical anaesthetic compositions |
SE7713618L (en) | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | LOCAL ANESTHETIC MIXTURE |
US4160827A (en) | 1978-02-06 | 1979-07-10 | The Upjohn Company | Metronidazole phosphate and salts |
US4229432A (en) | 1978-04-19 | 1980-10-21 | Bristol-Myers Company | Antiperspirant stick composition |
US4603812A (en) | 1978-06-27 | 1986-08-05 | The Dow Chemical Company | Foam-generating pump sprayer |
US4214000A (en) * | 1978-10-30 | 1980-07-22 | Johnson & Johnson | Zinc salt of all-trans-retinoic acid for the treatment of acne |
US4213979A (en) | 1978-12-18 | 1980-07-22 | Plough, Inc. | Stable sprayable hydrocortisone product |
US4954487A (en) | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4439441A (en) * | 1979-01-11 | 1984-03-27 | Syntex (U.S.A.) Inc. | Contraceptive compositions and methods employing 1-substituted imidazole derivatives |
US4226344A (en) | 1979-02-06 | 1980-10-07 | Booth, Inc. | Constant flow valve actuator |
CH639913A5 (en) | 1979-03-16 | 1983-12-15 | Aerosol Service Ag | Container for receiving and delivering a liquid substance |
US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4241048A (en) | 1979-05-01 | 1980-12-23 | Bristol-Myers Company | Suspension composition of benzocaine |
US4268499A (en) | 1979-06-07 | 1981-05-19 | Dow Corning Corporation | Antiperspirant emulsion compositions |
US4241149A (en) | 1979-07-20 | 1980-12-23 | Temple University | Canal clathrate complex solid electrolyte cell |
DE2931469A1 (en) | 1979-08-02 | 1981-02-26 | Bayer Ag | SURFACE SEALED MOLDED BODIES MADE OF CELLED POLYURETHANE ELASTOMERS AND METHOD FOR THE PRODUCTION THEREOF |
US4271149A (en) | 1979-09-21 | 1981-06-02 | West Agro-Chemical, Inc. | Germicidal iodine compositions with enhanced iodine stability |
US4299826A (en) | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
EP0032309A3 (en) | 1980-01-10 | 1981-08-05 | Imperial Chemical Industries Plc | Production of catalyst component, catalyst and use thereof |
US4309995A (en) | 1980-01-28 | 1982-01-12 | Sacco Susan M | Vaginal irrigation apparatus |
JPS56135416A (en) | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
US4508705A (en) | 1980-07-02 | 1985-04-02 | Lever Brothers Company | Skin treatment composition |
US4329990A (en) | 1980-08-07 | 1982-05-18 | Sneider Vincent R | Expanding swab applicator |
US4325939A (en) | 1980-09-22 | 1982-04-20 | Richardson-Vicks Inc. | Zinc derivatives and their use in dental compositions |
US4305936A (en) | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
US4292250A (en) | 1980-11-17 | 1981-09-29 | Wisconsin Alumni Research Foundation | Vitamin D derivatives |
DE3147726A1 (en) * | 1980-12-03 | 1982-06-24 | Leo Pharmaceutical Products Ltd. A/S (Loevens kemiske Fabrik Produktionsaktieselskab), 2750 Ballerup | ANTIBIOTIC COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE COMPOUNDS |
US4352808A (en) | 1980-12-12 | 1982-10-05 | Schering Corporation | 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore |
US4323694A (en) | 1981-04-13 | 1982-04-06 | Finetex, Inc. | Benzoic acid esters |
US4522948A (en) * | 1981-04-24 | 1985-06-11 | Syntex (U.S.A.) Inc. | Spermicidal substituted 1-(cycloalkyl)alkylimidazoles |
US4393066A (en) | 1981-06-05 | 1983-07-12 | Garrett David M | Method for treatment of herpetic lesions |
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US4469674A (en) | 1981-09-03 | 1984-09-04 | Richardson-Vicks Inc. | Stable oral compositions containing zinc and fluoride compounds |
US4440320A (en) | 1981-11-30 | 1984-04-03 | Wernicke Steven A | Foam dispensing apparatus |
LU83876A1 (en) | 1982-01-15 | 1983-09-02 | Oreal | COSMETIC COMPOSITION FOR TREATMENT OF KERATINIC FIBERS AND METHOD FOR TREATING THE SAME |
LU83949A1 (en) | 1982-02-16 | 1983-09-02 | Oreal | COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ANIONIC LATEX |
US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
US4529605A (en) * | 1983-01-12 | 1985-07-16 | Una E. Lynch | Bathing oil composition |
GB8315787D0 (en) | 1983-06-08 | 1983-07-13 | Briggs J H | Coolant spray |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
GB8330969D0 (en) | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
GB8402748D0 (en) | 1984-02-02 | 1984-03-07 | Dunlop Ltd | Intravaginal device |
US4985459A (en) | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
NZ207341A (en) | 1984-03-01 | 1988-02-29 | Harvey Alex Ind Ltd | Device containing chemical impregnants for insertion into a body cavity of an animal |
US4628063A (en) | 1984-03-08 | 1986-12-09 | Dana P. Brigham | Antiviral pharmaceutical preparations and methods for their use |
US4574052A (en) | 1984-05-31 | 1986-03-04 | Richardson-Vicks Inc. | Crackling aerosol foam |
GB8416638D0 (en) | 1984-06-29 | 1984-08-01 | Beecham Group Plc | Topical treatment and composition |
EP0172139B1 (en) | 1984-08-06 | 1988-09-14 | Ciba-Geigy Ag | Process for paper sizing with anionic hydrophobic sizing agents and cationic retention agents |
US4595526A (en) | 1984-09-28 | 1986-06-17 | Colgate-Palmolive Company | High foaming nonionic surfacant based liquid detergent |
SE8404895L (en) | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | MEANS OF A SENSITIVITY TEST |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
CA1261276A (en) | 1984-11-09 | 1989-09-26 | Mark B. Grote | Shampoo compositions |
US4701320A (en) | 1984-11-29 | 1987-10-20 | Lederle (Japan), Ltd. | Composition stably containing minocycline for treating periodontal diseases |
US4627973A (en) | 1984-12-14 | 1986-12-09 | Charles Of The Ritz Group Ltd. | Skin mousse |
AU5078885A (en) | 1984-12-20 | 1986-06-26 | Warner-Lambert Company | Non-irritant detergent |
US4673569A (en) | 1985-02-12 | 1987-06-16 | Faberge Incorporated | Mousse hair composition |
DE3670569D1 (en) | 1985-03-01 | 1990-05-31 | Procter & Gamble | Mild cleaning foam. |
US5002680A (en) | 1985-03-01 | 1991-03-26 | The Procter & Gamble Company | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits |
US4752465A (en) | 1985-09-20 | 1988-06-21 | Product Resources International, Inc. | Aerosol foam |
US4639367A (en) | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
US5094853A (en) | 1985-04-26 | 1992-03-10 | S. C. Johnson & Son, Inc. | Method of preparing a water-soluble stable arthropodicidally-active foam matrix |
DE3521713A1 (en) | 1985-06-18 | 1986-12-18 | Henkel KGaA, 4000 Düsseldorf | OIL-IN-WATER EMULSIONS WITH IMPROVED VISCOSITY BEHAVIOR |
US4672078A (en) | 1985-07-03 | 1987-06-09 | Schering-Plough Corporation | Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations |
US4806262A (en) | 1985-08-14 | 1989-02-21 | The Procter & Gamble Company | Nonlathering cleansing mousse with skin conditioning benefits |
AU6175586A (en) | 1985-09-11 | 1987-03-12 | Chesebrough-Pond's Inc. | Petroleum jelly, mild detergent anhydrous base compositions |
FR2591331A1 (en) | 1985-12-10 | 1987-06-12 | Drevet Jean Baptiste | Device for dispensing metered portions of a product contained in a pressurised receptacle |
US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
GB8607570D0 (en) | 1986-03-26 | 1986-04-30 | Euro Celtique Sa | Vaginal pharmaceutical preparation |
CA1291036C (en) | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
DE3614515A1 (en) | 1986-04-29 | 1987-11-05 | Pfeiffer Erich Gmbh & Co Kg | DISCHARGE DEVICE FOR MEDIA |
FR2598392B1 (en) | 1986-05-09 | 1988-08-26 | Oreal | PACKAGING FOR TWO PRESSURIZED CONTAINERS |
PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
US4770634A (en) | 1986-06-11 | 1988-09-13 | Pellico Michael A | Method for treating teeth with foamable fluoride compositions |
JPS62299423A (en) | 1986-06-18 | 1987-12-26 | Mazda Motor Corp | Air-conditioner for vehicle |
US4837019A (en) | 1986-08-11 | 1989-06-06 | Charles Of The Ritz Group Ltd. | Skin treatment composition and method for treating burned skin |
US4906453A (en) | 1986-08-12 | 1990-03-06 | Jumpeer Nails, Inc. | Mousse product |
DE3628531A1 (en) | 1986-08-22 | 1988-02-25 | Merz & Co Gmbh & Co | FOAMABLE CREAMS |
EP0270316A3 (en) | 1986-12-04 | 1989-12-06 | Pfizer Inc. | Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne |
US4822613A (en) | 1986-12-15 | 1989-04-18 | S. C. Johnson & Son, Inc. | Water-soluble foamable insecticidally-active compositions |
US4822614A (en) | 1986-12-19 | 1989-04-18 | S. C. Johnson & Son, Inc. | Bioactive film-forming composition for control of crawling insects and the like |
US5389677B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
US4863900A (en) | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
DE3704907A1 (en) | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
WO1988008316A1 (en) | 1987-04-21 | 1988-11-03 | Chattan Nominees Pty. Ltd. | Vaginal douche |
FR2615173B1 (en) | 1987-05-13 | 1989-08-18 | Valois | DOSING VALVE FOR LIQUID LOADED WITH A LIQUID OR LIQUEFIED GAS PROPELLER, FOR USE IN THE REVERSE POSITION |
US4867967A (en) | 1987-06-04 | 1989-09-19 | Crutcher Wilbert L | Method for the treatment of pseudofolliculitis barbae |
US4780309A (en) | 1987-06-16 | 1988-10-25 | Warner-Lambert Company | Edible aerosol foam compositions and method of preparing same |
US4849117A (en) * | 1987-06-17 | 1989-07-18 | Sanitek Products, Inc. | Concentrated composition for forming an aqueous foam |
US4885282A (en) | 1987-07-02 | 1989-12-05 | Thornfeldt Carl R | Treatment of hyperhidrosis, ichthyosis and wrinkling |
US4898246A (en) | 1987-07-06 | 1990-02-06 | Total Walther Feuerschutz Gmbh | Quick release valve for sprinkler head |
US5196405A (en) | 1987-07-08 | 1993-03-23 | Norman H. Oskman | Compositions and methods of treating hemorrhoids and wounds |
US4913893A (en) | 1987-08-28 | 1990-04-03 | Clairol Incorporated | Aerosol hair setting composition containing an alginate |
US4981677A (en) | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US4784842A (en) | 1987-09-25 | 1988-11-15 | Jean London | Therapeutic composition for treatment of cuts, burns and abrasions |
US5143717A (en) | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
JP2643217B2 (en) | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | Aqueous liquid of fat-soluble substance |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4897262A (en) | 1988-03-22 | 1990-01-30 | Playtex Jhirmack, Inc. | Non-aerosol hair spray composition |
DE3811081A1 (en) | 1988-03-30 | 1989-10-12 | Schering Ag | USE OF TOPIC APPLICABLE PREPARATIONS FOR THE TREATMENT OF AGING SKIN |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4873078A (en) | 1988-04-22 | 1989-10-10 | Plough, Inc. | High-gloss, high-shine lipstick |
GB8811409D0 (en) | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
US5378730A (en) | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US4827378A (en) | 1988-06-15 | 1989-05-02 | Rockwell International Corporation | Jack coaxial connector EMI shielding apparatus |
US5217707A (en) | 1988-06-16 | 1993-06-08 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Pharmaceutical composition and process for the preparation thereof |
US4902281A (en) | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
GB8821129D0 (en) | 1988-09-09 | 1988-10-12 | Unilever Plc | Cosmetic composition |
US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
GB8828013D0 (en) | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US4970067A (en) | 1988-12-12 | 1990-11-13 | Helene Curtis, Inc. | Method and composition to condition hair and impart semi-permanent hair set retention properties |
US5262407A (en) | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
FR2640942A1 (en) | 1988-12-23 | 1990-06-29 | Suchard Sa Jacobs | Container of the aerosol type for delivering, in the form of a foam, metered quantities of product, particularly of food product |
FR2641185B1 (en) * | 1988-12-29 | 1991-04-05 | Oreal | SHAVING COMPOSITION FOR THE SKIN BASED ON ACYLOXYALKYL FUNCTIONAL POLYORGANOSILOXANES AND METHOD FOR IMPLEMENTING SAME |
LU87449A1 (en) | 1989-02-09 | 1990-09-19 | Oreal | PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS |
US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
US5019375A (en) | 1989-03-14 | 1991-05-28 | The Procter & Gamble Company | Low residue antiperspirant creams |
US5221696A (en) | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
DE69020211T2 (en) | 1989-04-05 | 1995-11-02 | Kao Corp | Cosmetic double emulsion composition. |
US5071648A (en) | 1989-04-06 | 1991-12-10 | Merocel Corporation | Polymeric broad-spectrum antimicrobial materials |
US5204093A (en) | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
US5618798A (en) | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
GB8909559D0 (en) | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
US5322683A (en) | 1989-05-01 | 1994-06-21 | Leonard Mackles | Anhydrous aerosol foam |
US5002540A (en) | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
GB8911853D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Co2 blown integral skin foams |
US5208031A (en) | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
CA1337279C (en) | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
US5122519A (en) | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
MX21452A (en) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
US4981367A (en) | 1989-07-28 | 1991-01-01 | Stranco, Inc. | Portable mixing apparatus |
EP0484530B1 (en) | 1989-07-28 | 1995-07-12 | Hisamitsu Pharmaceutical Co., Inc. | Foamed aerosol preparation |
JPH0383914A (en) | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
US5219877A (en) | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
IL95952A0 (en) | 1989-10-19 | 1991-07-18 | Sterling Drug Inc | Aerosol composition for topical medicament |
US5508033A (en) * | 1989-12-06 | 1996-04-16 | Societe D'engrais Composes Mineraux Et Amendments | Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions |
US5295984A (en) | 1989-12-07 | 1994-03-22 | Ultrafem, Inc. | Vaginal discharge collection device and intravaginal drug delivery system |
US5422361A (en) * | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
US4966779A (en) | 1989-12-21 | 1990-10-30 | Basf Corporation | Stable, water miscible emulsion comprising a fat-soluble vitamin |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US4963351A (en) | 1989-12-26 | 1990-10-16 | Bhn Associates | Shaving aid |
US5100917A (en) | 1989-12-29 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | Novel a-nor-steroid-3-carboxylic acid derivatives |
US5104645A (en) | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
US5164367A (en) | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US5130121A (en) | 1990-04-17 | 1992-07-14 | Isp Investments Inc. | Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer |
US5007556A (en) | 1990-04-18 | 1991-04-16 | Block Drug Company, Inc. | Metering dispenser |
US5156765A (en) | 1990-05-15 | 1992-10-20 | Fox Valley Systems, Inc. | Aerosol foam marking compositions |
US5112359A (en) | 1990-06-04 | 1992-05-12 | Clairol, Inc. | Hair colorants |
JP3649341B2 (en) | 1990-06-15 | 2005-05-18 | 株式会社資生堂 | COMPOSITE AND COMPOSITE COMPOSITION, EMULSION COMPOSITION, AND EMULSION COMPOSITION |
US5034220A (en) | 1990-06-20 | 1991-07-23 | Gaf Chemicals Corporation | Non-aerosol shaving gel |
IT1243379B (en) | 1990-07-27 | 1994-06-10 | Giuliani Spa | PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL |
US5091111A (en) | 1990-09-19 | 1992-02-25 | S. C. Johnson & Son, Inc. | Aqueous emulsion and aersol delivery system using same |
US5114718A (en) | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
FR2668927B1 (en) | 1990-11-09 | 1993-01-08 | Oreal | COSMETIC ANHYDROUS COMPOSITION IN AEROSOL FORM FOR THE FORMATION OF A FOAM. |
DE9016291U1 (en) | 1990-11-30 | 1991-03-28 | Kali-Chemie Pharma Gmbh, 3000 Hannover, De | |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5227163A (en) | 1991-01-18 | 1993-07-13 | Clilco, Ltd. | Lice-repellant compositions |
DE4102506C2 (en) | 1991-01-29 | 1999-11-25 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
US5948682A (en) | 1991-02-22 | 1999-09-07 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US6753167B2 (en) | 1991-02-22 | 2004-06-22 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5650554A (en) | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
US5658956A (en) | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
US5663208A (en) | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
IT1247138B (en) | 1991-03-06 | 1994-12-12 | Dompe Farmaceutici Spa | HYDROPHILE PHARMACEUTICAL COMPOSITION CONTAINING KETOPROFENE LYSINE SALT FOR TOPICAL USE. |
US5279819A (en) * | 1991-03-18 | 1994-01-18 | The Gillette Company | Shaving compositions |
JPH06509559A (en) | 1991-03-19 | 1994-10-27 | セラピューティック パッチ リサーチ エヌ.ブイ. | Amino alcohol derivative compositions and methods as membrane permeation enhancers |
US5389676A (en) | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
AU658608B2 (en) | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
US5167950A (en) | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
DE4110973A1 (en) | 1991-04-05 | 1992-10-08 | Haarmann & Reimer Gmbh | MEDIUM WITH A PHYSIOLOGICAL COOLING EFFECT AND EFFECTIVE COMPOUNDS SUITABLE FOR THIS MEDIUM |
HU209605B (en) | 1991-04-15 | 1994-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of wather-free transdermal preparation |
IT1247529B (en) | 1991-04-24 | 1994-12-17 | Poli Ind Chimica Spa | PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION |
US5164357A (en) | 1991-06-05 | 1992-11-17 | Appleton Papers Inc. | Thermally-responsive record material |
GB9118028D0 (en) | 1991-08-21 | 1991-10-09 | Secr Defence Brit | Improved transdrmal formulations |
DE4127630A1 (en) | 1991-08-21 | 1993-02-25 | Bruno Jesswein | TWO-COMPONENT PRESSURE CAN, IN PARTICULAR FOR 2K FOAM |
US5643600A (en) | 1991-09-17 | 1997-07-01 | Micro-Pak, Inc. | Lipid vesicles containing avocado oil unsaponifiables |
WO1993005755A1 (en) | 1991-09-27 | 1993-04-01 | Nof Corporation | Cosmetic composition and emulsion composition |
GB2260079B (en) | 1991-10-01 | 1995-08-09 | American Cyanamid Co | Pharmaceutical composition containing felbinac |
US5230897A (en) | 1991-10-31 | 1993-07-27 | G. D. Searle & Co. | Transdermal pentamidine |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
DE4140474C2 (en) | 1991-12-09 | 1995-07-13 | Schuelke & Mayr Gmbh | Skincare additive |
IT1253711B (en) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS |
US5252246A (en) | 1992-01-10 | 1993-10-12 | Allergan, Inc. | Nonirritating nonionic surfactant compositions |
EP0552612A3 (en) | 1992-01-22 | 1993-10-20 | Hoffmann La Roche | Methods for determining and isolating compounds which bind directly to nucleosolic proteins |
RU2148647C1 (en) | 1992-04-02 | 2000-05-10 | Сембайозис Дженетикс Инк. | Method of expression of interesting dna sequence in seed cell, dna-structure, expression cassette, isolated regulatory site of transcription and method of alternation of specific metabolism in seeds |
US5344051A (en) | 1992-04-27 | 1994-09-06 | Insta-Foam Products, Inc. | Two-component foam dispensing apparatus |
ZA932947B (en) | 1992-04-28 | 1993-10-27 | Schering Plough Healthcare | Applicator for semisolid medications |
US5254334A (en) | 1992-05-04 | 1993-10-19 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters |
US5409706A (en) | 1992-05-04 | 1995-04-25 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters |
ZA933133B (en) | 1992-05-15 | 1994-10-05 | Akzo Nv | Application for introducing a cream-type substance into a woman's vagina |
JPH07506868A (en) | 1992-05-18 | 1995-07-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | coolant composition |
US5346135A (en) | 1992-06-16 | 1994-09-13 | Vincent Edward C | Spraying apparatus for blending liquids in a gaseous spray system |
US5300286A (en) * | 1992-07-14 | 1994-04-05 | Dow Corning Corporation | Silicone emulsion for personal care application |
KR950702436A (en) | 1992-07-28 | 1995-07-29 | 자코부스 코르넬리스 라세르 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER |
CA2105887C (en) | 1992-09-10 | 2004-03-16 | Peter Britton | Bioerodible device for administering active ingredients |
EP0660720A4 (en) | 1992-09-14 | 1996-12-27 | Walter P Smith | Skin-conditioning composition, its application and manufacture. |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5413775A (en) | 1992-09-29 | 1995-05-09 | Amerchol Corporation | Hairsprays and acrylic polymer compositions for use therein |
IT1255895B (en) | 1992-10-20 | 1995-11-17 | Laura Chiodini | PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN |
AU5541594A (en) | 1992-10-21 | 1994-05-09 | Gynetech Laboratories, Inc. | Vaginal sponge delivery system |
EP0596304B1 (en) | 1992-10-31 | 1998-04-01 | Th. Goldschmidt AG | Cosmetic and pharmaceutical compositions |
DE4238860A1 (en) | 1992-11-19 | 1994-05-26 | Medicon Gmbh | Skin protection products for the protection of human skin |
US5308643A (en) | 1992-11-30 | 1994-05-03 | Osipow Lloyd I | Self-lather generating shaving compositions |
JP3328344B2 (en) * | 1992-12-22 | 2002-09-24 | タイホー工業株式会社 | Method of controlling foaming state retention time of foaming type cleaning polishes |
JPH06263630A (en) | 1993-03-10 | 1994-09-20 | Lion Corp | Vitamin as-solubilizing eye drop |
DE4309900C1 (en) | 1993-03-26 | 1994-06-30 | Goldschmidt Ag Th | Process for the preparation of amphoteric surfactants |
JPH06279228A (en) | 1993-03-30 | 1994-10-04 | Kao Corp | Foaming composition |
US5326557A (en) | 1993-04-06 | 1994-07-05 | Dow Corning Corporation | Moisturizing compositions containing organosilicon compounds |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
EP0698393B1 (en) | 1993-05-19 | 2002-07-03 | Hisamitsu Pharmaceutical Co., Inc. | 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME |
BR9406411A (en) | 1993-05-21 | 1995-12-19 | Henkel Corp | Shampoo composition |
US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
US5384308A (en) | 1993-06-14 | 1995-01-24 | Henkin; R. I. | Composition and method for enhancing wound healing |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5398846A (en) | 1993-08-20 | 1995-03-21 | S. C. Johnson & Son, Inc. | Assembly for simultaneous dispensing of multiple fluids |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
FR2709666B1 (en) | 1993-09-07 | 1995-10-13 | Oreal | Cosmetic or dermatological composition consisting of an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating. |
JP2978043B2 (en) | 1993-09-16 | 1999-11-15 | 高砂香料工業株式会社 | (2S) -3-{(1R, 2S, 5R)-[5-methyl-2- (1-methylethyl) cyclohexyl] oxy} -1,2-propanediol, its production method and use |
US5766632A (en) * | 1993-10-01 | 1998-06-16 | Legere Pharmaceuticals, Ltd. | Method of using lectins for contraception |
FR2710854B1 (en) | 1993-10-08 | 1995-12-01 | Oreal | Oil-in-water emulsion usable for obtaining a cream. |
US5578315A (en) | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
FR2713486B1 (en) | 1993-12-14 | 1996-02-09 | Scophysa | New compositions for foams, in particular rectal foams, and foams thus obtained. |
ATE199215T1 (en) | 1993-12-23 | 2001-03-15 | Procter & Gamble | ANTIMICROBIAL COMPOSITIONS FOR WIPES |
US5527822A (en) | 1993-12-29 | 1996-06-18 | Forest Laboratories, Inc. | Method of treatment of traumatic brain injury |
DE9422052U1 (en) | 1994-01-04 | 1997-10-30 | Wuerth Adolf Gmbh & Co Kg | Filling device for filling a refillable dispensing container and refillable dispensing container |
DE4405127A1 (en) | 1994-02-18 | 1995-08-31 | Henkel Kgaa | Hair treatment products |
US5514367A (en) | 1994-02-28 | 1996-05-07 | Estee Lauder, Inc. | Skin tanning compositions and methods for their preparation and use |
US5925669A (en) | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
IL109230A (en) | 1994-04-05 | 1998-08-16 | Agis Ind 1983 Ltd | Anti-fungal composition containing bifonazole and fluocinonide |
US5658749A (en) | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
US5429815A (en) | 1994-04-11 | 1995-07-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Stable single-phase self-foaming cleanser |
FR2719467B1 (en) | 1994-05-05 | 1996-05-31 | Oreal | Use of flavonoids to preserve and / or strengthen the mechanical properties of the hair and method of protecting hair using these compounds. |
ES2079320B1 (en) | 1994-05-17 | 1996-10-16 | Cusi Lab | OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS. |
US5902574A (en) * | 1994-05-23 | 1999-05-11 | The Gillette Company | Shaving preparation for improved shaving comfort |
US5545401A (en) | 1994-06-02 | 1996-08-13 | Shanbrom; Edward | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine |
FR2720635B1 (en) | 1994-06-03 | 1996-07-26 | Oreal | Sunscreen cosmetic compositions and uses. |
US6221381B1 (en) | 1994-06-28 | 2001-04-24 | The University Of British Columbia | Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier |
MA23592A1 (en) | 1994-06-30 | 1995-12-31 | Procter & Gamble | COMPOSITIONS FOR BODY CARE CONTAINING THERMOPLASTIC ELASTOMERIC GRAFT COPOLYMERS |
US5679324A (en) | 1994-07-08 | 1997-10-21 | The Procter & Gamble Co. | Aerosol foamable fragrance composition |
FR2722431B1 (en) | 1994-07-12 | 1996-09-13 | Lir France Sa | DOUBLE DISPENSER FOR FLUID PRODUCTS |
US5869529A (en) | 1994-07-20 | 1999-02-09 | Agis Industries (1983) Ltd. | Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus |
JP3173330B2 (en) | 1994-07-20 | 2001-06-04 | トヨタ自動車株式会社 | Slip control device for vehicle lock-up clutch |
US5512555A (en) | 1994-07-21 | 1996-04-30 | Merck & Co., Inc. | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
JP3241542B2 (en) | 1994-07-29 | 2001-12-25 | 高砂香料工業株式会社 | Method for purifying (-)-n-isopulegol and citrus-based fragrance composition containing (-)-n-isopulegol obtained by the method |
DE4428096A1 (en) | 1994-08-09 | 1996-02-15 | Wella Ag | Two-chamber container |
US5656586A (en) | 1994-08-19 | 1997-08-12 | Rhone-Poulenc Inc. | Amphoteric surfactants having multiple hydrophobic and hydrophilic groups |
EP0777464A1 (en) | 1994-08-26 | 1997-06-11 | The Procter & Gamble Company | Personal cleansing compositions |
US5976555A (en) | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
JP3604177B2 (en) | 1994-09-14 | 2004-12-22 | 日東電工株式会社 | Transdermal formulation |
US5500211A (en) | 1994-09-22 | 1996-03-19 | The Gillette Company | Soap-free self-foaming shave gel composition |
US5905092A (en) | 1994-09-27 | 1999-05-18 | Virotex Corporation Reel/Frame | Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction |
US5955414A (en) | 1994-10-05 | 1999-09-21 | S. C. Johnson & Son, Inc. | Cleaning foam having fluorinated stain repellent and low flammability |
US5540853A (en) | 1994-10-20 | 1996-07-30 | The Procter & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
CA2180454A1 (en) | 1994-11-08 | 1996-05-17 | Toshihiko Terao | External preparation for skin protection |
US5567420A (en) | 1994-11-16 | 1996-10-22 | Mceleney; John | Lotion which is temporarily colored upon application |
US5788664A (en) | 1994-11-30 | 1998-08-04 | Scalise; Gaspare | Suppository applicator |
GB9424562D0 (en) | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
US5641480A (en) | 1994-12-08 | 1997-06-24 | Lever Brothers Company, Division Of Conopco, Inc. | Hair care compositions comprising heteroatom containing alkyl aldonamide compounds |
US5529770A (en) | 1994-12-09 | 1996-06-25 | West Agro, Inc. | Viscous liquid conditioning topical germicides |
DE4444238A1 (en) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
FR2728166A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P |
CA2208078C (en) | 1994-12-21 | 2009-06-23 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
DE4446891A1 (en) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stable aqueous budesonide solution |
US5616136A (en) | 1995-01-09 | 1997-04-01 | Med-Safe Systems, Inc. | Quick release needle removal apparatus |
US5534261A (en) | 1995-01-17 | 1996-07-09 | University Of Southern California | Retinoid-based compositions and method for preventing adhesion formation using the same |
FR2729855A1 (en) | 1995-01-26 | 1996-08-02 | Oreal | USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED |
US5523078A (en) | 1995-02-03 | 1996-06-04 | Michael E. Baylin | Method of preparing and composition for treatment of hair and scalp |
FR2730932B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY |
FR2730930B1 (en) | 1995-02-27 | 1997-04-04 | Oreal | USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD |
GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
US5783202A (en) | 1995-03-14 | 1998-07-21 | Soltec Research Pty. Ltd. | Pediculicidal mousse composition for killing head lice |
US6071536A (en) | 1995-03-29 | 2000-06-06 | Shionogi & Co., Ltd. | Gelatin capsule having adjusted water activity |
US5585104A (en) | 1995-04-12 | 1996-12-17 | The Procter & Gamble Company | Cleansing emulsions |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
FR2733417B1 (en) | 1995-04-25 | 1997-06-06 | Oreal | FOAMING OIL-IN-WATER EMULSION BASED ON NON-IONIC SURFACTANTS, A FATTY PHASE AND A CATIONIC OR ANIONIC POLYMER CROSS-LINKED AND USE IN TOPICAL APPLICATION |
GB9510856D0 (en) | 1995-05-27 | 1995-07-19 | Cussons Int Ltd | Cleaning composition |
EP2322137A1 (en) | 1995-06-22 | 2011-05-18 | Minnesota Mining And Manufacturing Company | Stable hydroalcoholic compositions |
JP3542665B2 (en) | 1995-07-07 | 2004-07-14 | 株式会社資生堂 | Anti-aging skin external preparation, collagen cross-linking inhibition skin external preparation and anti-ultraviolet skin external preparation |
FR2736824B1 (en) | 1995-07-18 | 1997-10-10 | Fabre Pierre Dermo Cosmetique | MINOXIDIL HAIR COMPOSITION WITH LOW FAT SOLVENT CONTENT |
DE29512760U1 (en) | 1995-08-08 | 1995-11-16 | Wella Ag | Pressurized gas container for dispensing foam |
TW504387B (en) | 1995-09-06 | 2002-10-01 | Kao Corp | Emulsified, water-in-oil type composition and skin cosmetic preparation |
US5881493A (en) | 1995-09-14 | 1999-03-16 | D. B. Smith & Co. Inc. | Methods for applying foam |
CN1062129C (en) | 1995-09-14 | 2001-02-21 | 徐荣祥 | Medicine matrix and its use |
US6221823B1 (en) * | 1995-10-25 | 2001-04-24 | Reckitt Benckiser Inc. | Germicidal, acidic hard surface cleaning compositions |
FR2742986B1 (en) | 1995-12-29 | 1998-01-30 | Rhone Poulenc Chimie | COSMETIC COMPOSITIONS FOR THE HAIR OR THE SKIN BASED ON SULPHONATED COPOLYESTERS WITH POLYORGANOSILOXANE MOTIFS |
US5716611A (en) | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5843411A (en) | 1997-02-06 | 1998-12-01 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
US5759524A (en) | 1996-02-09 | 1998-06-02 | The Procter & Gamble Company | Photoprotective compositions |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5912007A (en) | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
US6251369B1 (en) | 1996-03-05 | 2001-06-26 | Sultan Dental Products | Dental fluoride foam |
FR2745716B1 (en) | 1996-03-07 | 1998-04-17 | Oreal | ULTRAFINE PRESSURIZABLE FOAMING OIL-IN-WATER EMULSIONS |
US5910382A (en) | 1996-04-23 | 1999-06-08 | Board Of Regents, University Of Texas Systems | Cathode materials for secondary (rechargeable) lithium batteries |
IT1283042B1 (en) | 1996-05-21 | 1998-04-07 | Condea Augusta Spa | COSMETIC COMPOUNDS DEODORANT AND / OR ANTI-BREATHING |
US5797955A (en) | 1996-06-11 | 1998-08-25 | Walters; David J. | Pressure application unit for positioning vertebra |
US5833961A (en) | 1996-06-25 | 1998-11-10 | Inolex Investment Corporation | Polyester-based suncreen formulations |
EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
US5716621A (en) | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US5955408A (en) | 1996-07-10 | 1999-09-21 | Steris Inc. | Triclosan skin wash with enhanced efficacy |
DE19631221C2 (en) | 1996-08-02 | 1999-07-01 | Beiersdorf Ag | Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances |
WO1998006419A1 (en) | 1996-08-15 | 1998-02-19 | Southern Illinois University | Enhancement of antimicrobial peptide activity by metal ions |
US5833963A (en) | 1996-08-20 | 1998-11-10 | Bristol-Myers Squibb Company | Non-tacky and quick-drying aqueous-based antiperspirant compositions |
US5837270A (en) | 1996-08-26 | 1998-11-17 | Burgess; Nelson Leon | Topical anti-acne composition |
US6271295B1 (en) | 1996-09-05 | 2001-08-07 | General Electric Company | Emulsions of silicones with non-aqueous hydroxylic solvents |
US5952392A (en) | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
US7060253B1 (en) | 1996-09-20 | 2006-06-13 | Mundschenk David D | Topical formulations and delivery systems |
FR2754451B1 (en) | 1996-10-14 | 1998-11-06 | Oreal | SELF-FOAMING CREAM |
US6093408A (en) | 1996-10-25 | 2000-07-25 | The Procter & Gamble Company | Skin care compositions |
CA2275867A1 (en) | 1996-11-12 | 1998-05-22 | Tamarkin Pharmaceutical Innovation Ltd. | Method for treatment of dermatological disorders |
FR2755854B1 (en) | 1996-11-15 | 1998-12-24 | Oreal | NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES |
EP0889719B1 (en) | 1996-11-16 | 2003-04-02 | Wella Aktiengesellschaft | Agents for dying and decolorizing fibers |
US5951544A (en) | 1996-12-04 | 1999-09-14 | Laser Industries Ltd. | Handpiece assembly for laser apparatus |
US5759579A (en) | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
US5695551A (en) | 1996-12-09 | 1997-12-09 | Dow Corning Corporation | Water repellent composition |
US5856452A (en) | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
US5672634A (en) | 1996-12-23 | 1997-09-30 | Isp Investments Inc. | Crosslinked PVP-I2 foam product |
US5879469A (en) | 1997-01-06 | 1999-03-09 | Deeay Technologies Ltd. | Dishwashing method and detergent composition therefor |
IN186803B (en) | 1997-02-05 | 2001-11-10 | Panacea Biotec Ltd | |
ES2133090B1 (en) | 1997-02-21 | 2000-04-01 | Uriach & Cia Sa J | NEW APPLICATOR FOR THE ADMINISTRATION OF SEMI-SOLID MEDICATIONS. |
JP2002511058A (en) | 1997-02-10 | 2002-04-09 | バーナード・サラフスキ | Antiparasitic action of N, N-diethyl-m-toluamide (DEET) and a formulation that maintains its activity on the skin |
EP0969813B1 (en) | 1997-02-24 | 2004-09-29 | S.L.A. Pharma AG | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
JP3050289B2 (en) | 1997-02-26 | 2000-06-12 | 日本電気株式会社 | Output impedance adjustment circuit of output buffer circuit |
US5922331A (en) | 1997-03-26 | 1999-07-13 | Chanel, Inc. | Skin cream composition |
US5951989A (en) | 1997-04-07 | 1999-09-14 | Heymann; Warren R. | Method for the treatment of dry skin |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
IL132908A (en) | 1997-05-27 | 2002-07-25 | Sembiosys Genetics Inc | Method of emulsification of oil bodies and uses of the emulsion |
US6183762B1 (en) | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
EP0884045A1 (en) | 1997-06-06 | 1998-12-16 | Pfizer Products Inc. | Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
EP0993827A4 (en) | 1997-06-13 | 2006-07-05 | Taisho Pharmaceutical Co Ltd | Aerosols |
FR2765799B1 (en) | 1997-07-08 | 1999-08-27 | Oreal | GLOSSY COMPOSITION CONTAINING AROMATIC OILS THICKENED BY A POLYSACCHARIDE ALKYLETHER |
CA2300054C (en) | 1997-08-18 | 2003-09-30 | Neubourg, Stephanie | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
SE9703226D0 (en) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US5885581A (en) | 1997-09-11 | 1999-03-23 | Merz, Incorporated | Composition and method for improvement of the appearance of scars |
US6214318B1 (en) | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
FR2769299B1 (en) | 1997-10-03 | 1999-12-31 | Oreal | BI-PRODUCTS PACKAGING AND DISTRIBUTION SET |
US5961957A (en) | 1997-10-20 | 1999-10-05 | Mcanalley; Bill H. | Foam compositions |
US5911981A (en) | 1997-10-24 | 1999-06-15 | R.I.T.A. Corporation | Surfactant blends for generating a stable wet foam |
US5865347A (en) | 1997-10-27 | 1999-02-02 | William T. Wilkinson | Multi-chamber dispenser for flowable materials |
EP1027057A4 (en) | 1997-10-28 | 2003-01-02 | Vivus Inc | Treatment of female sexual dysfunction |
JP3450680B2 (en) | 1997-10-28 | 2003-09-29 | 高砂香料工業株式会社 | Method for producing para-menthane-3,8-diol |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
ES2318233T3 (en) | 1997-11-10 | 2009-05-01 | Strakan International Limited | IMPROVEMENT SYSTEMS OF PENETRATION AND IRRITATION REDUCERS THAT INCLUDE TESTOSTERONE. |
DE29720316U1 (en) | 1997-11-17 | 1998-01-29 | Andris Raimund Gmbh & Co Kg | Two-chamber dispenser |
US5849042A (en) | 1997-11-19 | 1998-12-15 | Bristol-Myers Squibb | Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol |
US5871720A (en) | 1997-11-20 | 1999-02-16 | Colgate-Palmolive Company | Cosmetic compositions with DBS and functionalized silicones |
FR2774595A1 (en) | 1998-02-06 | 1999-08-13 | Rech D Innovation Et De Dev Ce | EMULSION FOR TRANSDERMAL STEROID ADMINISTRATION |
DE19805918A1 (en) | 1998-02-13 | 1999-08-19 | Beiersdorf Ag | Lipidreduced preparations |
US6110966A (en) | 1998-02-20 | 2000-08-29 | Medi-Cell Laboratories, Inc. | Triple action complex |
DE19807774A1 (en) | 1998-02-24 | 1999-08-26 | Beiersdorf Ag | Use of flavone, flavanone or flavonoid compound for protection of ascorbic acid or ascorbyl compound against oxidation, especially in cosmetic and dermatological preparations, |
HU226610B1 (en) | 1998-03-04 | 2009-04-28 | Teijin Ltd | Activated vitamin d3 emulsion-type lotions |
US6121210A (en) | 1998-03-12 | 2000-09-19 | Dap Products Inc. | Foamable silicone oil compositions and methods of use thereof |
US5990100A (en) | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
US6649175B1 (en) | 1998-05-04 | 2003-11-18 | Schering-Plough Healthcare Products, Inc. | Skin barrier composition |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
US6146664A (en) | 1998-07-10 | 2000-11-14 | Shaklee Corporation | Stable topical ascorbic acid compositions |
DE19835239A1 (en) | 1998-08-04 | 2000-02-24 | Johnson & Johnson Gmbh | Foaming oil preparation and its use |
JP4017758B2 (en) | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | Cooling agent composition |
HUP0104168A3 (en) | 1998-08-20 | 2003-04-28 | 3M Innovative Properties Co | Spray on bandage and drug delivery system |
JP3712868B2 (en) | 1998-09-02 | 2005-11-02 | 株式会社カネボウ化粧品 | Aerosol composition |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
AUPP583198A0 (en) | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
AU760735B2 (en) | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
RU2134052C1 (en) | 1998-10-07 | 1999-08-10 | Нерушай Сергей Алексеевич | Method and apparatus for aerosol application of perfumery liquids |
US6287546B1 (en) * | 1998-10-09 | 2001-09-11 | Colgate-Palmolive Company | Shampoos with stabilizers |
JP3876081B2 (en) | 1998-10-22 | 2007-01-31 | 東洋エアゾール工業株式会社 | Aerosol composition for foam formation |
US6110477A (en) | 1998-10-30 | 2000-08-29 | Topix Pharmaceuticals Inc. | Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US5980904A (en) | 1998-11-18 | 1999-11-09 | Amway Corporation | Skin whitening composition containing bearberry extract and a reducing agent |
US6344218B1 (en) | 1998-11-23 | 2002-02-05 | The Procter & Gamble Company | Skin deodorizing and santizing compositions |
DE19855097A1 (en) | 1998-11-28 | 2000-05-31 | Wella Ag | Pigment-containing, foamable gel |
US20010006654A1 (en) | 1998-12-09 | 2001-07-05 | L'oreal | Compositions and methods for treating hair and skin using aqueous delivery systems |
US6087317A (en) | 1998-12-10 | 2000-07-11 | Dow Corning Corporation | Particle size stable silicone emulsions |
US6262128B1 (en) | 1998-12-16 | 2001-07-17 | 3M Innovative Properties Company | Aqueous foaming compositions, foam compositions, and preparation of foam compositions |
FR2787325B1 (en) | 1998-12-17 | 2001-01-26 | Oreal | NANOEMULSION BASED ON OXYETHYLENE OR NON-OXYETHYLENE SORBITAN FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
FR2787728B1 (en) | 1998-12-23 | 2001-01-26 | Oreal | NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
JP2000191429A (en) | 1998-12-28 | 2000-07-11 | Kao Corp | Foamable cosmetic |
FR2787703B1 (en) | 1998-12-29 | 2001-01-26 | Oreal | NANOEMULSION BASED ON ETHOXYL FATHER ETHERS OR ETHOXYL FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
FR2788007B1 (en) | 1999-01-05 | 2001-02-09 | Oreal | NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
FR2789371B1 (en) | 1999-02-05 | 2001-04-27 | Sofab | DISTRIBUTOR OF CHEMICALLY UNSTABLE PRODUCTS |
EP1025836A1 (en) | 1999-02-08 | 2000-08-09 | F. Hoffmann-La Roche Ag | Cosmetic light screening composition |
TWI262930B (en) | 1999-02-10 | 2006-10-01 | Mitsui Chemicals Inc | High-durability flexible polyurethane cold molded foam and process for producing the same |
US6224888B1 (en) | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
JP3641152B2 (en) | 1999-02-17 | 2005-04-20 | 株式会社ヤクルト本社 | Topical skin preparation |
EP1075325B1 (en) | 1999-02-26 | 2003-11-05 | Wella Aktiengesellschaft | Device for mixing, foaming and dispensing liquids from separate compressed-gas containers |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
IL129102A0 (en) | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
EP1040765B1 (en) | 1999-03-31 | 2006-10-04 | Firmenich Sa | Use of cubebol as a flavoring ingredient |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6433003B1 (en) | 1999-04-23 | 2002-08-13 | Arthur M. Bobrove | Method for treating hyperhidrosis in mammals |
GB9909711D0 (en) | 1999-04-27 | 1999-06-23 | Unilever Plc | Mousse forming hair treatment composition |
FR2793479B1 (en) | 1999-05-10 | 2001-06-29 | Lir France Sa | DOUBLE DISPENSER FOR FLUID OR PASTY PRODUCTS |
AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US6168576B1 (en) | 1999-05-24 | 2001-01-02 | Irene N. Reynolds | Device for dispensing vaginal medication |
US6518228B1 (en) | 1999-05-27 | 2003-02-11 | Clairol Incorporated | Ultra-mild, clear, aqueous, foamable skin cleanser |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
JP2000351726A (en) | 1999-06-08 | 2000-12-19 | Lion Corp | Aerosol preparation |
JP2000354623A (en) | 1999-06-14 | 2000-12-26 | Shiigeru Kk | Deodorant and deodorizing spray |
US6113888A (en) | 1999-06-15 | 2000-09-05 | Neutrogena Corporation | Self-tanning mousse |
US6190365B1 (en) | 1999-06-21 | 2001-02-20 | Chun Lim Abbott | Vaginal douche applicator and method of vaginal deodorization using the same |
JP2001002526A (en) | 1999-06-23 | 2001-01-09 | Koike Kagaku Kk | Foam aerosol composition |
US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
NL1012419C2 (en) | 1999-06-23 | 2000-12-28 | Airspray Nv | Aerosol for dispensing a liquid. |
US6762158B2 (en) | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
FR2795643B1 (en) | 1999-07-02 | 2004-06-11 | Oreal | FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID |
JP4058199B2 (en) | 1999-07-06 | 2008-03-05 | ポーラ化成工業株式会社 | Warm feeling pack |
US6548074B1 (en) | 1999-07-22 | 2003-04-15 | Elizabeth Arden Co., Division Of Conopco, Inc. | Silicone elastomer emulsions stabilized with pentylene glycol |
FR2796925B1 (en) | 1999-07-29 | 2001-10-05 | Valois Sa | DISPENSER WITH ARTICULATED DISPENSING HEAD |
DE19938757A1 (en) | 1999-08-16 | 2001-02-22 | Beiersdorf Ag | Cosmetic or dermatological preparations of the oil-in-water type |
US6777591B1 (en) | 1999-08-27 | 2004-08-17 | Sembiosys Genetics Inc. | Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter |
US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
US6308863B1 (en) | 1999-09-02 | 2001-10-30 | Owens-Brockway Plastic Products Inc. | Dual chamber package for pressurized products |
JP4394775B2 (en) | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | Water-in-oil foam aerosol composition and method for producing the same |
JP4045475B2 (en) | 1999-09-06 | 2008-02-13 | 東洋紡績株式会社 | Nucleic acid / protein purification equipment |
US6437006B1 (en) | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
FR2798849B1 (en) | 1999-09-29 | 2001-11-23 | Oreal | COMPOSITION FOR WASHING KERATIN MATERIALS, BASED ON A DETERGENT SURFACE-ACTIVE AGENT, A DIALKYL DIALLYL AMMONIUM HOMOPOLYMER AND AN ACRYLIC TERPOLYMER |
US6790435B1 (en) | 1999-10-01 | 2004-09-14 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Antiperspirant compositions comprising microemulsions |
US6667045B2 (en) | 1999-10-01 | 2003-12-23 | Joseph Scott Dahle | Topical applications for skin treatment |
FR2799369B1 (en) | 1999-10-08 | 2001-12-21 | Oreal | COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF |
US6186367B1 (en) | 1999-10-19 | 2001-02-13 | Valley Design Inc. | Metered liquid squeeze dispenser |
FR2799963B1 (en) | 1999-10-22 | 2002-07-19 | Oreal | EMULSIONS CONTAINING AT LEAST ONE INSOLUBLE ORGANIC UV FILTER AND A NON-FILTERING ORGANOMODIFIED SILICONE |
US6080394A (en) | 1999-11-08 | 2000-06-27 | Dow Corning Corporation | Polar solvent-in-oil emulsions and multiple emulsions |
UA66796C2 (en) | 1999-12-27 | 2004-06-15 | Univ Nat Pharmaceutical | Composition "profesol foamy" for treating radiation lesions of skin |
IL133969A0 (en) | 2000-01-10 | 2001-04-30 | Thixo Ltd | Thixotropic compositions containing unsaturated oils and food products containing the same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
FR2804016B1 (en) | 2000-01-21 | 2006-07-28 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND PEG ESTER AND USES THEREOF |
FR2804015B1 (en) | 2000-01-21 | 2005-12-23 | Oreal | NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND NONIONIC POLYMER AND USES THEREOF |
US6780443B1 (en) | 2000-02-04 | 2004-08-24 | Takasago International Corporation | Sensate composition imparting initial sensation upon contact |
FR2804666B1 (en) | 2000-02-04 | 2002-06-14 | Oreal | DISPENSER FOR STORING AT LEAST TWO COMPONENTS AND SELECTIVE DISPENSING EITHER OF A SINGLE CONSTITUENT, EITHER OF THEIR MIXTURE, AND METHOD FOR THE IMPLEMENTATION THEREOF |
US20040161447A1 (en) | 2000-02-17 | 2004-08-19 | Leonard Paul | Liquid foam producing compositions and dispensing system therefor |
JP4764588B2 (en) | 2000-02-22 | 2011-09-07 | カラー アクセス,インコーポレイティド | Gelled aqueous cosmetic composition |
EP1269357A4 (en) | 2000-02-22 | 2005-10-12 | Metacarta Inc | Spatially coding and displaying information |
US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
IL135222A (en) | 2000-03-22 | 2005-06-19 | Univ Ben Gurion | Compositions containing molecular iodine |
DE20006099U1 (en) | 2000-04-01 | 2000-07-06 | Megaplast Gmbh & Co Kg | Dosing pump dispenser with at least two dosing pumps |
US6649571B1 (en) | 2000-04-04 | 2003-11-18 | Masi Technologies, L.L.C. | Method of generating gas bubbles in oleaginous liquids |
FR2807322B1 (en) | 2000-04-10 | 2004-02-20 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING ASCORBIC ACID IN ASSOCIATION WITH AN ASCORBIC ACID DERIVATIVE |
JP2002012513A (en) | 2000-04-24 | 2002-01-15 | Kanebo Ltd | Urea-containing whipped cosmetic |
US6358541B1 (en) | 2000-05-03 | 2002-03-19 | David S. Goodman | Topical preparation for the treatment of hair loss |
US6410036B1 (en) | 2000-05-04 | 2002-06-25 | E-L Management Corp. | Eutectic mixtures in cosmetic compositions |
CA2408112A1 (en) | 2000-05-08 | 2001-11-15 | Pfizer Products Inc. | Skin protectant spray compositions |
US6433024B1 (en) | 2000-05-08 | 2002-08-13 | Karl F. Popp | Topical anti-acne composition |
FR2808685B1 (en) | 2000-05-12 | 2004-10-08 | Sanofi Synthelabo | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS |
JP2001326952A (en) | 2000-05-15 | 2001-11-22 | Nec Corp | Broadcast confirmation system, method and device for broadcast confirmation, and recording medium with broadcast confirmation program recorded thereon |
FR2809010B1 (en) | 2000-05-22 | 2002-07-12 | Oreal | NANOEMULSION BASED ON ANIONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
JP4653282B2 (en) | 2000-05-23 | 2011-03-16 | 昭和薬品化工株式会社 | Minocycline-containing composition |
DE10028638A1 (en) | 2000-06-09 | 2001-12-20 | Schuelke & Mayr Gmbh | Storage-stable composition useful in cosmetic and pharmaceutical compositions comprises combination of glycerol monoalkyl ether with antioxidant |
CA2313659A1 (en) | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
DE10033414B4 (en) | 2000-07-08 | 2004-02-19 | Wella Aktiengesellschaft | Clear, two-phase, foam-forming aerosol hair care product |
FR2811564B1 (en) | 2000-07-13 | 2002-12-27 | Oreal | NANOEMULSION CONTAINING NON-IONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
DE10035930A1 (en) | 2000-07-21 | 2002-01-31 | Clariant Gmbh | fine emulsions |
US20020035070A1 (en) | 2000-07-26 | 2002-03-21 | The Procter & Gamble Company | Method of regulating hair growth using metal complexes of oxidized carbohydrates |
FR2812191B1 (en) | 2000-07-28 | 2003-10-17 | Oreal | USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS |
JP4166931B2 (en) | 2000-08-02 | 2008-10-15 | ポーラ化成工業株式会社 | Fever foam cosmetic |
US6514487B1 (en) | 2000-08-08 | 2003-02-04 | Teresa Leigh Barr | Foam and gel oat protein complex and method of use |
US6299023B1 (en) | 2000-08-24 | 2001-10-09 | Miles Arnone | Device for dispensing two substances in a user selectable ratio with replaceable cartridges |
FR2813189B1 (en) | 2000-08-31 | 2003-02-28 | Oreal | COSMETIC FOAMING CREAM FOR THE TREATMENT OF OILY SKIN |
WO2002022086A2 (en) | 2000-09-14 | 2002-03-21 | Quantum Energy Technologies | Application of water nanoclusters to skin |
DE10049147A1 (en) | 2000-10-04 | 2002-04-25 | Wella Ag | Hair wax product with waxes, non-volatile oils and volatile, hydrophobic substances |
FR2814959A1 (en) | 2000-10-09 | 2002-04-12 | Menarini France | Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve |
US6547063B1 (en) | 2000-10-10 | 2003-04-15 | The Procter & Gamble Company | Article for the delivery of foam products |
GB2367809A (en) | 2000-10-12 | 2002-04-17 | Bespak Plc | Metering valve with collapsible chamber |
FR2815616B1 (en) | 2000-10-20 | 2003-01-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTEMPORARY DISTRIBUTION OF TWO PRODUCTS |
US6403069B1 (en) | 2000-10-20 | 2002-06-11 | Colgate-Palmolive Company | High oil clear emulsion with elastomer |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
DE10058384B4 (en) | 2000-11-24 | 2004-12-16 | Wella Aktiengesellschaft | Cosmetic or dermatological agent in the form of a creamy permanent foam or a stably foamed cream, its use and method for producing the agent |
US6299032B1 (en) | 2000-11-27 | 2001-10-09 | George W. Hamilton | Disposable actuator with cap opener for aerosol cans |
US6969521B1 (en) | 2000-11-28 | 2005-11-29 | Avon Products, Inc. | Aerosol insect repellent composition having low VOC content and method of applying same to the skin |
US20050013853A1 (en) | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
GB0030068D0 (en) | 2000-12-11 | 2001-01-24 | Lawrence Malcolm | Highway vehicular traffic flow control |
JP3497466B2 (en) | 2000-12-12 | 2004-02-16 | 高砂香料工業株式会社 | Warming composition |
US20060254597A1 (en) | 2000-12-14 | 2006-11-16 | 40J's Llc | Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound |
US6749860B2 (en) | 2000-12-22 | 2004-06-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with non-aqueous compositions containing botanicals |
US20040079361A1 (en) | 2001-01-17 | 2004-04-29 | Clayton Colin D. | Medicinal aerosols |
FR2819427B1 (en) | 2001-01-18 | 2003-04-11 | Oreal | TRANSLUCENT NANOEMULSION, MANUFACTURING METHOD THEREOF AND USES THEREOF IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS |
KR20100036390A (en) | 2001-03-06 | 2010-04-07 | 셀러지 파마세우티칼스, 인크 | Compounds and methods for the treatment of urogenital disorders |
WO2002076414A2 (en) | 2001-03-07 | 2002-10-03 | The Procter & Gamble Company | Cosmetic topical composition comprising a functional aromatic derivative bonding agent |
AU2002254396A1 (en) | 2001-03-26 | 2002-10-08 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
US6640805B2 (en) | 2001-03-26 | 2003-11-04 | 3M Innovative Properties Company | Metering valve for a metered dose inhaler having improved flow |
NZ528377A (en) | 2001-03-27 | 2005-05-27 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
JP2002302419A (en) | 2001-03-30 | 2002-10-18 | Aldeep Cosmetics Japan Inc | Cosmetic composition |
US6848597B2 (en) | 2001-04-18 | 2005-02-01 | James A. Vlodek | Methods and apparatus for extruding foam through orifices |
US6682726B2 (en) | 2001-04-30 | 2004-01-27 | The Gillette Company | Self-foaming shaving lotion |
US20020187181A1 (en) | 2001-05-14 | 2002-12-12 | 3M Innovative Properties Company | System for delivering cosmetics and pharmaceuticals |
ITMI20011019A1 (en) | 2001-05-17 | 2002-11-17 | Carlo Ghisalberti | FURILIC SUBSTANCES FOR TOPICAL USE |
US7270828B2 (en) | 2001-06-20 | 2007-09-18 | The Procter & Gamble Company | Personal care composition comprising hydrophobic gel |
FR2826292B1 (en) | 2001-06-22 | 2004-01-23 | Rhodia Chimie Sa | OIL-IN-OIL EMULSIONS COMPRISING A SILICONE, DISPERSIONS OF SUCH EMULSIONS AND USE THEREOF |
US6544562B2 (en) | 2001-06-25 | 2003-04-08 | Blistex Inc. | Acne treatment including dual-package system |
US6428772B1 (en) | 2001-06-25 | 2002-08-06 | Blistex Inc. | Acne treatment composition with cooling effect |
JP2003012511A (en) | 2001-06-27 | 2003-01-15 | Rohto Pharmaceut Co Ltd | Aerosol composition |
WO2003002426A1 (en) | 2001-06-27 | 2003-01-09 | Kanebo,Limited | Mixer/extractor |
WO2003005985A1 (en) | 2001-07-13 | 2003-01-23 | The Procter & Gamble Company | Mousse forming compositions comprising quaternary ammonium agents |
DE10134786A1 (en) | 2001-07-17 | 2003-02-06 | Beiersdorf Ag | Foamable preparations |
US7960416B2 (en) | 2001-08-03 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Stable emulsion composition |
DE10138495B4 (en) | 2001-08-04 | 2004-11-11 | Beiersdorf Ag | Foaming preparations and their use |
WO2003013475A1 (en) | 2001-08-08 | 2003-02-20 | Garcia-Olmedo Dominguez Maria | Injectable foam and novel pharmaceutical applications thereof |
JP4707279B2 (en) | 2001-08-09 | 2011-06-22 | ポーラ化成工業株式会社 | Cosmetics for massage with cool-down effect |
US7091243B2 (en) | 2001-08-09 | 2006-08-15 | Croda, Inc. | Anti-irritants |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US20030049218A1 (en) | 2001-08-28 | 2003-03-13 | Amit Patel | Antiperspirant deodorant emulsion |
EP1455888B1 (en) | 2001-08-29 | 2009-04-29 | PharmaKodex Limited | Topical administration device |
US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
FR2829693B1 (en) | 2001-09-20 | 2004-02-27 | Oreal | FOAMING COSMETIC CREAM |
DE10147820A1 (en) | 2001-09-27 | 2003-04-10 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids which are solid and / or semi-solid at room temperature |
US7931533B2 (en) | 2001-09-28 | 2011-04-26 | Igt | Game development architecture that decouples the game logic from the graphics logics |
US20030185839A1 (en) | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
EP1434836B1 (en) | 2001-10-10 | 2013-01-16 | ExxonMobil Research and Engineering Company | Biodegradable non-toxic gear oil |
EP1438946B1 (en) | 2001-10-26 | 2009-01-14 | Taiyo Kagaku Co., Ltd. | Composition for oily foamable aerosol |
DE10154324A1 (en) | 2001-11-06 | 2003-08-07 | Merz Pharma Gmbh & Co Kgaa | Topically applicable compositions with external active substance depot formation, their production and their use |
DE10155956A1 (en) | 2001-11-09 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations |
MXPA04004478A (en) | 2001-11-13 | 2004-08-11 | Procter & Gamble | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care. |
EP1565189A4 (en) | 2001-11-16 | 2006-11-02 | Beatrice M Klysz | Anti-aging skin care composition and uses thereof |
DE10159002A1 (en) | 2001-11-30 | 2003-06-18 | Clariant Gmbh | Use of multi-phase foaming agents from foam dispensers |
FR2833246B1 (en) | 2001-12-06 | 2005-06-24 | Beatrice France Touteau | DEVICE FOR SIMULTANEOUSLY ACTING TWO AEROSOLS CONTAINING TWO PRODUCTS TO BE MIXED AT THE TIME OF USE |
US6531118B1 (en) | 2001-12-11 | 2003-03-11 | Avon Products, Inc. | Topical compositions with a reversible photochromic ingredient |
US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
US20030118515A1 (en) | 2001-12-21 | 2003-06-26 | Robert Jew | Cosmetic composition containing carbon dioxide |
US20030129259A1 (en) | 2001-12-28 | 2003-07-10 | Avon Products, Inc. | Topical lightening compostitions and methods of use |
JP4549625B2 (en) | 2002-01-05 | 2010-09-22 | 株式會社アモーレパシフィック | Finely emulsified particles containing ginseng saponin metabolites as active ingredients, a method for producing the same, and a cosmetic composition for preventing skin aging containing the same |
US7192601B2 (en) | 2002-01-18 | 2007-03-20 | Walker Edward B | Antimicrobial and sporicidal composition |
US6992049B2 (en) | 2002-01-31 | 2006-01-31 | Exxonmobil Research And Engineering Company | Lubricating oil compositions |
NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
CN100396684C (en) | 2002-02-14 | 2008-06-25 | 基姆逊有限公司 | Aluminium and hexa methylene tetramine composite and application thereof |
US6589216B1 (en) | 2002-02-20 | 2003-07-08 | Abbott Research Group, Inc. | Vaginal douches, vaginal douche applicators and methods of vaginal douching |
US6691898B2 (en) | 2002-02-27 | 2004-02-17 | Fomo Products, Inc. | Push button foam dispensing device |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US20050281766A1 (en) | 2002-03-11 | 2005-12-22 | Avon Products, Inc. | Method of improving the aesthetic appearance of epithelia |
US6848601B2 (en) | 2002-03-14 | 2005-02-01 | Homax Products, Inc. | Aerosol systems and methods for mixing and dispensing two-part materials |
BR0308530B1 (en) | 2002-03-19 | 2014-02-18 | COMBINATION OF A FIRST CONTAINER AND A SECOND CONTAINER TO FORM A MINISTRY UNIT, MINISTRY UNIT, AND A CONTAINER FOR A NET SUBSTANCE | |
US20030180347A1 (en) | 2002-03-19 | 2003-09-25 | W.F. Young, Incorporated | Patch for the delivery of topical agents |
JP4322124B2 (en) | 2002-03-28 | 2009-08-26 | 伯東株式会社 | Method for stabilizing bubbles in foam-containing cosmetics |
EP1496773B1 (en) | 2002-04-12 | 2006-08-30 | Dreamwell, Ltd. | Cassette bedding system |
US6875438B2 (en) | 2002-04-27 | 2005-04-05 | Aventis Pharma Deutschland Gmbh | Preparations for topical administration of substances having antiandrogenic activity |
US20030215472A1 (en) | 2002-05-16 | 2003-11-20 | Bonda Craig A | Methods and compositions employing a dialkyl amide |
US6838778B1 (en) * | 2002-05-24 | 2005-01-04 | Hamilton Sundstrand Corporation | Integrated starter generator drive having selective torque converter and constant speed transmission for aircraft having a constant frequency electrical system |
JP4050094B2 (en) | 2002-05-28 | 2008-02-20 | 株式会社三谷バルブ | Metering valve mechanism and aerosol products |
US6723309B1 (en) | 2002-06-10 | 2004-04-20 | Jeffrey Alan Deane | Hair cleansing conditioner |
FR2840903B1 (en) | 2002-06-13 | 2005-01-28 | Oreal | GLUCOSE AND VITAMIN F DERIVATIVE, COMPOSITIONS COMPRISING THE SAME, AND USES FOR IMPROVING THE CONDITION OF HAIR AND HAIR |
US7763587B2 (en) | 2002-06-13 | 2010-07-27 | L'oreal S.A. | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
AU2003244078B2 (en) | 2002-06-26 | 2009-05-14 | Daizo Co., Ltd. | Packaging container for discharge of plurality of contents, packaging product including the packaging container and process for producing the packaging product |
US6785629B2 (en) | 2002-07-02 | 2004-08-31 | Agilent Technologies, Inc. | Accuracy determination in bit line voltage measurements |
JP3833972B2 (en) | 2002-07-08 | 2006-10-18 | 古河電気工業株式会社 | Wire harness assembly system |
US7137536B2 (en) | 2002-07-22 | 2006-11-21 | Seaquist Perfect Dispensing Foreign, Inc. | Inverted aerosol dispenser |
DE10233330B4 (en) | 2002-07-22 | 2007-04-26 | Sasol Germany Gmbh | Microemulsion containing UV photoprotective filter and / or anti-dandruff agent |
US20020182162A1 (en) | 2002-08-07 | 2002-12-05 | Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
FR2843373B1 (en) | 2002-08-12 | 2005-03-04 | Jean Augustin | DEVICE FOR PACKAGING AND APPLYING A PRODUCT IN FLUID FORM |
US7939170B2 (en) | 2002-08-15 | 2011-05-10 | The Rockefeller University | Water soluble metal and semiconductor nanoparticle complexes |
US6770607B2 (en) * | 2002-09-12 | 2004-08-03 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Viscoelastic cleansing gel with micellar surfactant solutions |
US7906473B2 (en) | 2002-09-13 | 2011-03-15 | Bissell Homecare, Inc. | Manual spray cleaner |
GB0221697D0 (en) | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
US6968982B1 (en) | 2002-09-18 | 2005-11-29 | Burns Caleb E S | Multiple-mist dispenser |
US7179481B2 (en) | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US6949037B2 (en) | 2002-09-27 | 2005-09-27 | Richard A. Enos | Quick-release fastener for releasably attaching lacrosse stick head to shaft |
FR2845672B1 (en) | 2002-10-09 | 2006-02-10 | Airlessystems | FLUID PRODUCT DISPENSER |
US8232304B2 (en) | 2002-10-24 | 2012-07-31 | G & R Pharmaceuticals, Llc | Antifungal formulations |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20080317679A1 (en) | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20070292359A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
US20050205086A1 (en) | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20080206161A1 (en) | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20060193789A1 (en) | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20070292355A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20080031907A1 (en) | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
CN1300095C (en) | 2002-10-28 | 2007-02-14 | 吉万奥丹股份有限公司 | Coolant solutions and compositions comprising the sameitle |
JP2004250435A (en) | 2002-11-21 | 2004-09-09 | Dai Ichi Seiyaku Co Ltd | Composition for hair growth |
AU2003293865A1 (en) | 2002-12-12 | 2004-06-30 | Allpresan Gesellschaft Zum Vertrieb Von Gesundheitsprodukten Fur Allergiker Mbh | Stable foam cream |
GB0229071D0 (en) | 2002-12-13 | 2003-01-15 | Unilever Plc | Cosmetic method and composition for enhancing attractiveness |
US20040191196A1 (en) | 2002-12-16 | 2004-09-30 | Dov Tamarkin | Novel conjugate compounds and dermatological compositions thereof |
FR2848847B1 (en) | 2002-12-18 | 2005-10-14 | Coletica | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF |
FR2848998B1 (en) | 2002-12-20 | 2006-04-07 | Oreal | DISPENSING DEVICE HAVING MEANS FOR DISTRIBUTING TWO PRODUCTS IN VARIABLE PROPORTIONS |
CA2764405A1 (en) | 2003-01-02 | 2004-07-22 | Femmepharma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
EA009031B1 (en) | 2003-01-24 | 2007-10-26 | Стифел Рисерч Оустрэйлиа Пти Лтд. | Clindamycin phosphate based foam |
US20040151756A1 (en) | 2003-02-04 | 2004-08-05 | Richards Anthony P. | Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle |
EP1603560A1 (en) | 2003-02-06 | 2005-12-14 | Cipla Ltd. | Topical immunotherapy and compositions for use therein |
MXPA05008479A (en) | 2003-02-12 | 2006-03-10 | Connetics Australia Pty Ltd | Film foaming hydroalcoholic foam. |
GB0305010D0 (en) | 2003-03-05 | 2003-04-09 | Unilever Plc | Changing colours |
US6843390B1 (en) | 2003-03-17 | 2005-01-18 | Joe G. Bristor | Multiple fluid closed system dispensing device |
US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
WO2004084905A2 (en) | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
WO2004084973A2 (en) | 2003-03-24 | 2004-10-07 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
DE10315936A1 (en) | 2003-04-03 | 2004-10-28 | Ing. Erich Pfeiffer Gmbh | Discharge device for at least one medium |
US20040229803A1 (en) | 2003-04-22 | 2004-11-18 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
US20040220187A1 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
DE10319771B4 (en) | 2003-05-02 | 2005-03-17 | Koenig & Bauer Ag | System for inspecting a printed image |
JP2004353084A (en) | 2003-05-08 | 2004-12-16 | Sanyo Electric Co Ltd | Evaporator fixation member |
FR2854821B1 (en) | 2003-05-16 | 2006-12-08 | Oreal | ASSEMBLY FOR PACKAGING AND DISPENSING A PRODUCT, IN PARTICULAR IN THE FORM OF A SAMPLE |
JP4232535B2 (en) | 2003-05-20 | 2009-03-04 | セイコーエプソン株式会社 | Printer maintenance system, print control server, client, method related thereto and program related thereto |
US7222802B2 (en) | 2003-05-23 | 2007-05-29 | Meadwestvaco Corporation | Dual sprayer with external mixing chamber |
US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
JP4018032B2 (en) | 2003-06-17 | 2007-12-05 | 高砂香料工業株式会社 | Hair and body cleaning composition |
CA2524739A1 (en) | 2003-06-18 | 2004-12-29 | Galderma S.A. | Metronidazole-based green tinted topical pharmaceutical composition |
KR100727327B1 (en) | 2003-06-19 | 2007-06-12 | 더 프록터 앤드 갬블 캄파니 | Polyol-in-silicone emulsions |
US6967012B2 (en) | 2003-06-25 | 2005-11-22 | General Motors Corporation | Imide/amide hydrogen storage materials and methods |
US20050042182A1 (en) | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20070140999A1 (en) | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US7226230B2 (en) | 2003-07-28 | 2007-06-05 | Raymond Liberatore | Spreader |
US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
MXPA06001381A (en) | 2003-08-04 | 2006-05-19 | Foamix Ltd | Foam carrier containing amphiphilic copolymeric gelling agent. |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
MXPA06002163A (en) | 2003-08-25 | 2006-05-22 | Foamix Ltd | Penetrating pharmaceutical foam. |
ATE386091T1 (en) | 2003-09-05 | 2008-03-15 | Univ Rice William M | FLUORESCENT SECURITY INKS AND MARKERS WITH CARBON NANOTUBE |
US20060140990A1 (en) | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
CN1886126A (en) | 2003-09-25 | 2006-12-27 | Dmi生物科学公司 | Methods and products which utilize N-acyl-L-aspartic acid |
US20050084551A1 (en) | 2003-09-26 | 2005-04-21 | Jensen Claude J. | Morinda citrifolia-based oral care compositions and methods |
FR2860143B1 (en) | 2003-09-26 | 2008-06-27 | Oreal | COSMETIC COMPOSITION COMPRISING A SEQUENCE POLYMER AND A NON-VOLATILE SILICONE OIL |
EA200600666A1 (en) | 2003-09-29 | 2006-10-27 | Этена Хелткеа Инк. | GEL AND WOODY COMPOSITIONS WITH HIGH ALCOHOL CONTENT |
GB2406330B (en) | 2003-09-29 | 2005-12-07 | Bespak Plc | A dispensing apparatus |
MXPA06003743A (en) | 2003-10-03 | 2006-06-23 | Collegium Pharmaceutical Inc | Topical aerosol foams. |
FR2860502B1 (en) | 2003-10-07 | 2007-09-14 | Valois Sas | DOSING VALVE AND DEVICE FOR DISPENSING FLUID PRODUCT COMPRISING SUCH A VALVE |
GB0323908D0 (en) | 2003-10-11 | 2003-11-12 | Nupharm Lab Ltd | Pharmaceutical foam formulation |
FR2860976B1 (en) | 2003-10-20 | 2006-02-10 | Ravi Shrivastava | NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS. |
US7419498B2 (en) | 2003-10-21 | 2008-09-02 | Nmt Medical, Inc. | Quick release knot attachment system |
CN100475184C (en) | 2003-10-31 | 2009-04-08 | 宝洁公司 | Skin care composition containing dehydroacetic acid and skin care actives |
US8157788B2 (en) | 2003-11-06 | 2012-04-17 | Paolo L. Manfredi | Multi-site drug delivery platform |
DE10354051A1 (en) | 2003-11-17 | 2005-06-16 | Beiersdorf Ag | Dispensers containing cosmetic preparations containing aids for keeping the donor in motion |
US7905673B2 (en) | 2003-11-17 | 2011-03-15 | The Procter & Gamble Company | Antiperspirant composition and applicator therefor |
US20050115988A1 (en) | 2003-12-01 | 2005-06-02 | Brian Law | Multiple liquid foamer |
US20050123496A1 (en) | 2003-12-08 | 2005-06-09 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Self foaming non-aqueous personal wash cleansers with little or no surfactant |
DE10361022A1 (en) | 2003-12-23 | 2005-07-28 | Merckle Gmbh Chem.-Pharm. Fabrik | Topical preparations containing dimethyl sulfoxide and dexpanthenol |
ATE478082T1 (en) | 2003-12-30 | 2010-09-15 | Gilead Sciences Inc | PHOSPHONATES, MONOPHOSPHONAMIDATE, BISPHOSPHONAMIDATE FOR THE TREATMENT OF VIRAL DISEASES |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
US20050186147A1 (en) * | 2004-02-04 | 2005-08-25 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US7225518B2 (en) | 2004-02-23 | 2007-06-05 | Boston Scientific Scimed, Inc. | Apparatus for crimping a stent assembly |
JP4381169B2 (en) | 2004-02-27 | 2009-12-09 | 花王株式会社 | Hair cosmetics |
PT2985039T (en) | 2004-03-03 | 2018-11-09 | Revance Therapeutics Inc | Topical application and transdermal delivery of botulinum toxins |
US7510345B2 (en) | 2004-03-18 | 2009-03-31 | Bodypoint Designs, Inc. | Quick release assembly |
DE102004016710B4 (en) | 2004-04-05 | 2020-11-19 | Greppmayr GmbH | Foot care formulation |
US9168224B2 (en) | 2004-04-08 | 2015-10-27 | Meda Pharma Sarl | Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
EP1737429B1 (en) | 2004-04-19 | 2013-07-17 | Strategic Science & Technologies, LLC | Transdermal delivery of beneficial substances effected by a high ionic strength environment |
NL1026031C2 (en) | 2004-04-23 | 2005-10-25 | Airspray Nv | Delivery assembly. |
CA2565754A1 (en) | 2004-04-28 | 2005-10-28 | Foamix Ltd. | Body cavity foams |
US20050244354A1 (en) | 2004-04-30 | 2005-11-03 | Sam Speron | Oxygenated personal care products |
JP2005314323A (en) | 2004-04-30 | 2005-11-10 | Sato Pharmaceutical Co Ltd | Hair growth formulation |
WO2005115336A2 (en) | 2004-05-15 | 2005-12-08 | Collegium Pharmaceutical, Inc. | Sprayable formulations for the treatment of acute inflammatory skin conditions |
US7083125B2 (en) | 2004-05-17 | 2006-08-01 | S.C. Johnson & Son, Inc. | Detachable tube assembly |
US7143909B2 (en) | 2004-05-21 | 2006-12-05 | Sonoco Development, Inc. | Reconfigurable metered material dispenser |
US8394394B2 (en) | 2004-05-26 | 2013-03-12 | L'oréal | Mousse formulations |
ITBO20040338A1 (en) | 2004-05-28 | 2004-08-28 | Progine Farmaceutici Srl | VAGINAL NEBULIZATION DISPENSER |
US20050268416A1 (en) | 2004-06-03 | 2005-12-08 | Sommers J E | Foldable lotion applicator |
JP4368250B2 (en) | 2004-06-09 | 2009-11-18 | ポーラ化成工業株式会社 | Post-form dosage form of warm cosmetic |
FR2871696B1 (en) | 2004-06-17 | 2006-11-10 | Galderma Sa | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS |
US8211449B2 (en) | 2004-06-24 | 2012-07-03 | Dpt Laboratories, Ltd. | Pharmaceutically elegant, topical anhydrous aerosol foam |
JP4355264B2 (en) | 2004-06-25 | 2009-10-28 | ポーラ化成工業株式会社 | Warm feeling non-water foam cosmetic |
US7207655B2 (en) | 2004-06-28 | 2007-04-24 | Eastman Kodak Company | Latency stirring in fluid ejection mechanisms |
US20060008432A1 (en) | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
UA93354C2 (en) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Topical antiviral formulations |
US20060121073A1 (en) | 2004-07-12 | 2006-06-08 | Sandhya Goyal | Topical gel formulation comprising insecticide and its preparation thereof |
US7288692B2 (en) | 2004-07-14 | 2007-10-30 | Exxonmobil Chemcial Patents Inc. | Process for producing olefins |
MXPA06014390A (en) | 2004-07-19 | 2007-10-02 | Warner Lambert Co | Formulation for stimulating hair growth. |
JP4557624B2 (en) | 2004-07-29 | 2010-10-06 | 株式会社吉野工業所 | Quantitative dispenser |
US20060029565A1 (en) | 2004-08-09 | 2006-02-09 | The Gillette Company | Self-heating shave foam product |
JP5087773B2 (en) | 2004-08-12 | 2012-12-05 | トリアクセス テクノロジーズ インコーポレイテッド | Optical signal detection circuit and method |
EP2438910A1 (en) | 2004-08-31 | 2012-04-11 | Stiefel Research Australia Pty Ltd | Microemulsion & sub-micron emulsion process & compositions |
KR100623013B1 (en) | 2004-09-04 | 2006-09-19 | 김영대 | Nano-emulsion, the use thereof, and preparing method thereof |
TR201907874T4 (en) | 2004-09-23 | 2019-06-21 | Arc Medical Devices Inc | Pharmaceutical compositions and methods for inhibiting fibrous adhesions or inflammatory diseases using low sulphate fucans. |
FR2875797B1 (en) | 2004-09-30 | 2006-11-24 | Oreal | DISTRIBUTION ASSEMBLY FOR THE EXTENDED DISTRIBUTION OF TWO PRODUCTS |
BRPI0404595A (en) | 2004-10-26 | 2006-06-13 | Natura Cosmeticos Sa | oil-in-water nanoemulsion, cosmetic composition and cosmetic product comprising same, process for preparing said nanoemulsion |
DE102004052986A1 (en) | 2004-11-02 | 2006-05-04 | Lindal Ventil Gmbh | Device for mixing two different components |
US7350673B2 (en) | 2004-11-19 | 2008-04-01 | Glynntech, Inc. | Metered dose squeeze dispenser |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
BRPI0607038A2 (en) | 2005-01-28 | 2009-12-01 | Basf Ag | use of polymers cosmetic compositions for hair and skin and dermatological composition |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
US20060193813A1 (en) | 2005-02-11 | 2006-08-31 | L'oreal | Nanoemulsion containing a hydroxylated urea compound |
GB0506141D0 (en) | 2005-03-24 | 2005-05-04 | Transphase Ltd | A topical compostion and its uses |
US20060222675A1 (en) | 2005-03-29 | 2006-10-05 | Sabnis Ram W | Personal care compositions with color changing indicator |
CA2610135A1 (en) | 2005-04-19 | 2006-10-19 | Foamix Ltd. | Apparatus and method for releasing a measured amount of content from a container |
JP5348749B2 (en) | 2005-05-05 | 2013-11-20 | ジェネンコー・インターナショナル・インク | Personal care compositions and methods for their use |
WO2007054818A2 (en) | 2005-05-09 | 2007-05-18 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
CA2608023C (en) | 2005-05-10 | 2015-08-18 | Dermipsor Ltd. | Compositions comprising calcipotriol and nicotinamide for treating hyperproliferative epidermal diseases |
US20060272199A1 (en) * | 2005-06-02 | 2006-12-07 | Bmc Manufacturing, Llc | Aqueous gel candle for use with a warming device |
US20070009607A1 (en) | 2005-07-11 | 2007-01-11 | George Jones | Antibacterial/anti-infalmmatory composition and method |
EP2862560B1 (en) | 2005-07-18 | 2019-10-30 | The Procter and Gamble Company | Aerosol cream mousse, method of treating hair and use |
US20080152596A1 (en) | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
CN100531515C (en) | 2005-07-22 | 2009-08-19 | 鸿富锦精密工业(深圳)有限公司 | Printing circuit board with modified power zone block |
CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
WO2007025244A2 (en) | 2005-08-25 | 2007-03-01 | Houle Philip R | Treatment systems for delivery of sensitizer solutions |
WO2007119099A2 (en) | 2005-09-12 | 2007-10-25 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
FR2890559B1 (en) | 2005-09-13 | 2011-06-24 | Galderma Sa | DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION |
DE202006004676U1 (en) | 2005-09-28 | 2007-02-08 | Neubourg Skin Care Gmbh & Co. Kg | Formulation, useful as foam skin cream and to treat e.g. dermatitis and psoriasis, comprises an aqueous emulsion, propellant gas, urea emulsion, hyaluronic acid, free fatty acid and at least two emulsions |
EP2100601B1 (en) | 2005-10-24 | 2012-06-27 | Precision Dermatology, Inc. | Topical pharmaceutical foam composition |
US20070134174A1 (en) | 2005-11-03 | 2007-06-14 | Christopher Irwin | Personal care composition |
JP2007131539A (en) | 2005-11-08 | 2007-05-31 | Koike Kagaku Kk | Chilling foam cosmetic |
US20070148194A1 (en) | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
JP4885529B2 (en) | 2005-12-08 | 2012-02-29 | 住友重機械工業株式会社 | Radiation detection unit and radiation inspection apparatus |
US20070160548A1 (en) | 2005-12-13 | 2007-07-12 | Playtex Products, Inc. | Moisturizing sunless tanning composition |
US20070142263A1 (en) | 2005-12-15 | 2007-06-21 | Stahl Katherine D | Color changing cleansing composition |
US20070148112A1 (en) | 2005-12-28 | 2007-06-28 | Avon Products, Inc. | Foaming, color-changing topical composition and method of imparting a cosmetic effect |
JP2009536920A (en) | 2006-03-22 | 2009-10-22 | ザ プロクター アンド ギャンブル カンパニー | Aerosol products comprising a foamable concentrate composition comprising particulate matter |
AU2007273935B2 (en) | 2006-03-31 | 2011-08-18 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
US20070264317A1 (en) | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
WO2007142967A2 (en) | 2006-05-31 | 2007-12-13 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
WO2008110872A2 (en) | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US7826675B2 (en) | 2006-07-04 | 2010-11-02 | Hewlett-Packard Development Company, L.P. | Feature-aware image defect removal |
MX2009000507A (en) | 2006-07-14 | 2009-06-12 | Stiefel Res Australia Pty Ltd | Fatty acid pharmaceutical foam. |
AU2007275815A1 (en) | 2006-07-18 | 2008-01-24 | Wirra Ip Pty. Ltd. | Immune response modifier formulations |
US20080031908A1 (en) | 2006-07-25 | 2008-02-07 | L'oreal | Oily cosmetic composition in aerosol form |
JP2008040899A (en) | 2006-08-08 | 2008-02-21 | Fuji Xerox Co Ltd | Printing controller, program, and method |
JP2010502690A (en) | 2006-09-08 | 2010-01-28 | フォーミックス エルティーディー. | Colored or colorable foamable composition |
HUP0600765A2 (en) | 2006-10-06 | 2008-10-28 | Istvan Piller | Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080206155A1 (en) | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
AU2007355106A1 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
US20080153789A1 (en) | 2006-12-26 | 2008-06-26 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
US20080292560A1 (en) | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
US20080188445A1 (en) | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
US20080188446A1 (en) | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
FR2915891B1 (en) | 2007-05-10 | 2012-05-11 | Oreal | FOAM COMPOSITION COMPRISING A SILICONE POLYMER |
US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8617100B2 (en) | 2007-09-04 | 2013-12-31 | Foamix Ltd. | Device for delivery of a foamable composition |
US20090130029A1 (en) | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
CA2711703A1 (en) | 2008-01-08 | 2009-07-16 | Foamix Ltd. | Sensation modifying topical composition foam |
AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
ES2330291B1 (en) | 2008-02-29 | 2010-10-18 | Lipotec Sa | USEFUL PEPTIDES IN THE TREATMENT OF SKIN, MUCOSAS AND / OR LEATHER HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS. |
RU2547441C2 (en) | 2008-03-06 | 2015-04-10 | Анакор Фармасьютикалз, Инк. | Boron-containing small molecules as anti-inflammatory agents |
US8253882B2 (en) | 2008-08-07 | 2012-08-28 | Sharp Kabushiki Kaisha | Display device |
JP5213734B2 (en) | 2009-01-22 | 2013-06-19 | サンウエーブ工業株式会社 | Cabinet with flap door |
BRPI1008037B1 (en) | 2009-02-25 | 2019-08-06 | Stiefel Research Australia Pty Ltd. | Oil-in-water emulsion aerosol foam composition, use of said composition for treating a skin condition, disorder or condition and process for preparing said composition |
-
2005
- 2005-04-06 US US11/099,942 patent/US8486376B2/en active Active
-
2013
- 2013-06-06 US US13/911,470 patent/US20130295022A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5635469A (en) * | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
US5705472A (en) * | 1995-07-18 | 1998-01-06 | Petroferm Inc. | Neutral aqueous cleaning composition |
US5939376A (en) * | 1997-09-25 | 1999-08-17 | Colgate Palmolive Company | Liquid cleaning compositions containing an organic ester foam control agent |
US6551604B1 (en) * | 1999-06-28 | 2003-04-22 | The Procter & Gamble Company | Skin care compositions |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080138296A1 (en) * | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10716740B2 (en) | 2015-03-24 | 2020-07-21 | The Procter & Gamble Company | Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
Publication number | Publication date |
---|---|
US8486376B2 (en) | 2013-07-16 |
US20050244342A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8486376B2 (en) | Moisturizing foam containing lanolin | |
US20190307685A1 (en) | Nonsteroidal immunomodulating kit and composition and uses thereof | |
US20190307656A1 (en) | Foam containing unique oil globules | |
US11103454B2 (en) | Wax foamable vehicle and pharmaceutical compositions thereof | |
US20140182585A1 (en) | Aerosol container for foamable compositions | |
US9539208B2 (en) | Foam prepared from nanoemulsions and uses | |
US9439857B2 (en) | Foam containing benzoyl peroxide | |
US20050205086A1 (en) | Retinoid immunomodulating kit and composition and uses thereof | |
US9492412B2 (en) | Penetrating pharmaceutical foam | |
US10117812B2 (en) | Foamable composition combining a polar solvent and a hydrophobic carrier | |
US20060193789A1 (en) | Film forming foamable composition | |
US20130189196A1 (en) | Foamable Composition | |
AU2006283225A1 (en) | Vasoactive kit and composition and uses thereof | |
WO2007085902A2 (en) | Foamable composition combining a polar solvent and a hydrophobic carrier | |
ZA200502180B (en) | Penetrating pharmaceutical foam | |
AU2007356328A1 (en) | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses | |
AU2006201878A1 (en) | Foamable composition for hyperhidrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FOAMIX LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRIEDMAN, DORON;BESONOV, ALEX;TAMARKIN, DOV;AND OTHERS;REEL/FRAME:030786/0623 Effective date: 20050605 |
|
AS | Assignment |
Owner name: FOAMIX PHARMACEUTICALS LTD., ISRAEL Free format text: CHANGE OF NAME;ASSIGNOR:FOAMIX LTD.;REEL/FRAME:033445/0249 Effective date: 20140601 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PERCEPTIVE CREDIT HOLDINGS II, LP, NEW YORK Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:FOAMIX PHARMACEUTICALS LTD.;REEL/FRAME:052130/0966 Effective date: 20200309 |
|
AS | Assignment |
Owner name: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.), NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PERCEPTIVE CREDIT HOLDINGS II, LP;REEL/FRAME:057531/0980 Effective date: 20210811 |